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Abstract 
Heteroclitic peptides are sequence variants of native peptide epitopes that stimulate T 
cell responses superior to the native epitope. Since heteroclitic peptides enhance HIV-
specific CD8+ T cell cytokine production, we investigated whether they reduce signs 
of HIV-specific CD8+ T cell exhaustion. Twenty-four variant peptides were generated 
from reference human histocompatibility-linked leukocyte antigen (HLA)-A2-
restricted peptide epitopes Nef 8391, Nef 135143, Gag 433440 and Gag 
7785 with conservative and semi-conservative amino acid substitutions at positions 
3, 5 and 7 or 3, 5 and 8 of Gag 433440. Variants that enhanced interferon-gamma 
(IFN-γ) and/or interleukin-2 (IL-2) production were tested for their effects on 
proliferation and programmed death-1 (PD-1) expression. Heteroclitic variants 
enhanced HIV-specific CD8+ T cell proliferation by > 20% in 13/29 cases, induced 
lower PD-1 expression by 15% - 50% in 10 cases, and by ≥ 50% in 3 cases. These 
data indicate unique immunotherapeutic potential for heteroclitic peptides. 
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1.0 Introduction 
1.1 Overview of HIV/AIDS 
1.1.1 Discovery 
Acquired Immunodeficiency Syndrome (AIDS) was first observed in the 
United States in the early 1980’s among previously healthy young intravenous drug 
users and gay men who developed Pneumocystis jiroveci pneumonia (PJP), 
opportunistic cryptococcal or cytomegalovirus infections or rare malignancies like 
Kaposi’s sarcoma that normally occur only in immunocompromised patients (1). The 
rising incidence of PJP and Kaposi’s sarcoma in an unusual population prompted the 
task force team formed at the US Centers for Disease Control and Prevention (CDC) 
to monitor the outbreak and the term Acquired Immune Deficiency Syndrome was 
coined to name the fatal disease in 1982 (2,3). 
Françoise Barré-Sinoussi and Robert Gallo independently isolated the etiologic 
agent of AIDS and published their findings in the same issue of Science in 1983 (4,5). 
While Barré-Sinoussi’s group named the agent lymphadenopathy-associated virus 
(LAV), Gallo's group named it human T cell lymphotropic virus, type 3 (HTLV-III) 
(6). A consensus was reached in May 1986 by the International Committee on the 
Taxonomy of Viruses, and the name human immunodeficiency virus (HIV) was 
adopted (7). 
 Outbreaks of wasting and severe infections were also observed in rhesus 
macaques (Macaca mulatta) by researchers at the California Regional Primate 
Research Center (CRPRC) and New England Regional Primate Research Center 
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(NERPRC) shortly after the discovery of human-AIDS (8,9). These symptoms were 
similar to those observed in AIDS patients and the disease was termed simian-AIDS 
(10). Western Blot cross-reactivity between HIV-1 antigens and sera from these 
macaques led to the discovery and naming of the causative agent of simian-AIDS as 
simian immunodeficiency virus (SIV) (8,11). Sera from Senegalese sex-workers 
preferentially cross-reacted with SIV antigens on Western Blot assay as opposed to 
HIV-1 antigens, suggesting exposure to a more SIV-like virus (12). A similar but 
immunologically distinct strain of HIV was subsequently isolated from West African 
AIDS patients from Guinea-Bissau and Cape Verde in 1986. This strain was named 
HIV-2 and it has since remained endemic in West Africa (13). 
 
1.1.2 Epidemiology 
 The Joint United Nations Programme on HIV/AIDS (UNAIDS) recently 
reported that approximately 35.3 [32.2 – 38.8] million people were living with HIV 
worldwide at the end of 2012. There were 2.3 [1.9 – 2.7] million new infections and 
about 1.6 [1.4 – 1.9] million deaths due to AIDS in 2012 alone. About 95% of the new 
infections were in low and middle income countries. The sub-Saharan African region 
appears to be worst affected by this infection, accounting for 57% of people living 
with HIV worldwide (14). 
 Since the first reported case of HIV in Canada in 1985, a cumulative total of 
76,275 positive HIV tests have been reported to the Public Health Agency of Canada 
(PHAC). A total of 2,062 new infections were reported in 2012, which represents a 
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7.8% decrease from the 2011 reports (2,237 cases) and is the lowest number of annual 
HIV cases since incidence was first reported in 1985 (15). 
 
1.1.3 Structure and Genome 
 HIV is a lentivirus that belongs to the Retroviridae family. Viruses belonging 
to the lentivirus genus typically establish infection with a long incubation period 
(lente-, Latin for "slow") before development of disease. The mature HIV particle is 
spherical, about 100-120 nm in diameter and enveloped with a lipid bi-layer 
membrane derived from the host cell during budding of a newly formed virion.  
Within the nucleocapsid are two identical copies of a single-stranded, positive-sense 
ribonucleic acid (RNA) genome of ~9.7 kb. The nine genes (gag, pol, env, tat, rev, 
nef, vif, vpr, and vpu) that encode HIV proteins can be found in each copy of the 
RNA. Flanking both ends of the RNA are long terminal repeat (LTR) sequences, 
which regulate HIV replication. The structural proteins are encoded by the group-
specific core antigen (gag) and envelope (env) genes. The Gag gene codes for the 
matrix protein (p17), capsid (p24) and nucleocapsid (p7). The Pol gene encodes 
catalytic proteins such as reverse transciptase, protease and integrase. The Env gene 
encodes the glycoprotein (gp) 160, which is cleaved to the outer envelope protein 
gp120 and transmembrane protein gp41. Trans-activator of transcription (tat) and 
regulator of viral expression (rev) are both regulatory genes. Other genes such as vpu, 
vif, vpr and nef are accessory genes. The function of these genes and their products are 
summarized in Table 1.1, and discussed in relation to the HIV life cycle below. 
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Figure 1.1: HIV structure (A) the envelope proteins (gp120, gp41), RNA genome 
and other regulatory proteins. (B) The single-stranded HIV RNA genome showing the 
nine major genes coding for the viral proteins flanked on both sides by the LTR long-
terminal repeat. 
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Table 1.1: The nine major genes of HIV highlighting their products and function. 
Adapted by permission from Macmillan Publishers Ltd (16). 
Gene Protein Class Protein/Function 
gag – group specific 
antigen 
 
 
 
 
 
 
 
 
 
Structural 
Matrix (p17) 
*Undergoes myristylation 
that targets Gag 
polyprotein to lipid rafts 
*Implicated in nuclear 
import of HIV 
preintegration complex 
(PIC) 
Capsid (p24) 
*forms the inner core-
protein layer 
Nucleocapsid (p7) 
*binds directly to genomic 
RNA 
p6 
*Interacts with Vpr 
*Contains late domain 
(PTAP) that binds TSG101 
and participates in terminal 
steps of virion budding 
pol – polymerase  
 
Enzyme 
Protease (p10) 
*cleaves gag precursor 
Reverse Transcriptase 
(p66/51) 
Integrase (p32) 
env – envelope  
 
 
 
 
Envelope 
gp160 envelope protein 
cleaved in endoplasmic 
reticulum to 
gp120 
*protrudes from envelope 
and binds CD4 and 
chemokine receptor 
gp41 
*Transmembrane protein 
associated with gp120 and 
required for fusion 
tat – transactivator  
 
 
 
p14/p16 
*Binds transactivation 
response element 
*Enhances RNA Pol II 
elongation on the viral 
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DNA template in presence 
of host cyclin T1 and 
CDK9 
rev – regulator of viral 
gene expression 
Regulatory 
 
p19 
*Binds rev responsive 
element 
*Allows export of 
unspliced and singly 
spliced mRNAs from 
nucleus 
vif – viral infectivity factor  p23 
*Promotes infectivity of 
viral particle 
*Depletes intracellular 
stores of the anti-retroviral 
factors APOBEC3G, thus 
blocking virion 
incorporation of this factor 
vpr – viral protein R  p15 
*Promotes G2 cell cycle 
arrest 
*Facilitates HIV infection 
of macrophages 
vpu – viral protein U Accessory *Required for efficient 
viral assembly 
*Promotes CD4 
degradation 
*Influences budding of 
virion 
nef – negative regulation 
factor 
 *Downregulates host-cell 
CD4 and MHC Ι 
expression 
*Blocks apoptosis 
*Alters state of cellular 
activation 
*Progression to disease 
slowed significantly in 
absence of Nef 
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1.1.4 Life Cycle and Pathogenesis 
 Viral attachment and entry is initiated when gp120 binds specifically to CD4 
molecules expressed on certain T cells, macrophages and dendritic cells (17). The 
gp120/CD4 binding triggers a structural change, which permits the interaction of 
gp120 chemokine binding domains with either CC chemokine receptor 5 (CCR5) or 
CXC chemokine receptor 4 (CXCR4) (18,19). Selective interaction with one or the 
other of these chemokine receptors determines the virus tropism. M-tropic or R5 
strains utilize the CD4 molecule and β-chemokine receptor CCR5 to infect target 
cells, whereas the T-tropic or X4 strains utilize the CD4 molecule and α-chemokine 
receptor CXCR4. Viruses that utilize both chemokine receptors are defined as X4/R5 
strains (18,20). 
 The viral gp120 undergoes a conformational change upon binding with the 
relevant coreceptor. This change exposes the underlying transmembrane gp41, which 
in turn inserts its hydrophobic NH2 terminal sequence into the target cell membrane to 
initiate viral fusion with the target cell (21,22). After successful target cell infection 
and virus particle uncoating, reverse transcriptase (rt) converts the single-stranded 
RNA genome into a double-stranded cDNA copy. Approximately one mutation is 
introduced for every 1000–10,000 nucleotides synthesized due to the error-prone 
reverse transcription process (23-25). The cDNA forms a pre-integration complex 
(PIC) with host proteins (such as barrier to autointegration factor 1) and viral proteins 
(such as vpr, matrix and integrase), is actively transported to the nucleus and 
integrated into the host genome as a “provirus” by integrase (26,27). The provirus is 
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replicated as part of the host cell genome or may lie dormant and persist for several 
years in the latent stage of HIV infection. 
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Figure 1.2: The life cycle of HIV. The HIV particle fuses with the host cell 
membrane through interactions of gp120, gp41, CD4 and CCR5 and/or CXCR4. This 
is followed by uncoating and release of the viral genomic contents into the host cell 
cytoplasm. Reverse transcription produces a viral cDNA, which is translocated into 
the nucleus where it integrates with the host DNA. Copies of viral RNA are made 
following the activation and gene transcription of the host cell DNA. Viral proteins 
are made from viral RNAs. In the cytoplasm, the viral proteins mature and assemble 
into viral particles that bud from the host cell membrane.  Figure adapted from (28). 
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Human tripartite motif 5 alpha (TRIM5α) is a host protein that acts to inhibit 
HIV-1 replication soon after uncoating by targeting the capsid for ubiquitination and 
rapid proteolytic degradation. Viral replication commences postintegration with the 
production of nascent viral transcripts by cellular RNA polymerases. Transcription is 
initiated with the binding of cellular transcription factors (such as NFκB) to the 5’ end 
of the LTR which now serves as the promoter region. Translation of these early 
transcripts results in the production of regulatory proteins such as tat, rev and nef. Tat 
induces transcription by binding to transactivation response (TAR) element. Rev 
facilitates the nuclear export of unspliced RNA transcripts and Nef downregulates 
expression of CD4 and MHC class I molecules (29).  
Accessory proteins such as Vpu enhance CD4 degradation and facilitate virion 
release by inhibiting the host factor tetherin (30). Vpr enhances cell cycle arrest at the 
G2/M phase and can disrupt cellular transcription (31). Vif promotes infectivity of the 
virion and targets host cytidine deaminases (APOBEC3G and APOBEC3F) for 
ubiquitination and proteosomal degradation (32). Full length viral transcripts are 
packaged into the immature viral particles assembled into their functional forms by 
protease. The p6 protein which is present on the c-terminus of Gag interacts with 
tumor suppressor gene 101 (TSG101) to facilitate budding of the newly assembled 
viral particles (33).  
HIV replication kinetics can raise viremia to more than 100 million HIV-1 
RNA copies/ml plasma in the first few weeks of infection. This stage is known as the 
acute or primary phase of HIV-infection which is often characterized by flu-like 
symptoms. 
11 
 
 
 
 
 
Figure 1.3: Pathogenesis of untreated HIV-1 infection. There is a progressive spike 
in plasma viremia during acute infection with HIV. This leads to a continuous decline 
in CD4+ T cell count, with no detectable presence of neutralizing HIV-1 antibodies. 
The viremia is initially controlled by the host immune response (not shown), and the 
subject then enters a phase of clinical latency (chronic phase). HIV-specific antibodies 
are detectable at the onset of this stage. Viral replication continues, but the immune 
system is able to contain it to set-point levels (not illustrated). Total CD4+ T cell 
numbers continue to decline and untreated individuals develop clinical symptoms of 
full-blown AIDS over time. Reproduced with permission from (34) Copyright 
Massachusetts Medical Society. 
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There are no detectable neutralizing antibodies against HIV-1 during primary 
infection and the first evidence of an HIV-specific CD8+ T cell immune response is 
observed towards the end of this phase (35-37). During the asymptomatic phase, there 
are no overt clinical symptoms of on-going infection even though the viral replication 
cycle continues and there is usually a dramatic decline in the systemic CD4+ T cell 
count in untreated individuals (38). The emergence of HIV-specific CD8+ T cells is 
associated with decline of viremia to low levels, but destruction of CD4+ T cells 
continues, especially, within the lymphoid tissues of the gut (39). If left untreated, the 
CD4+ T cells are often reduced below a certain threshold level that permits the 
development of opportunistic infections (OIs). This phase could last from a few 
months to more than 15 years (36,40). 
 AIDS is often defined as the chronic terminal stage of HIV infection. The 
CD4+ T cell count falls to < 200 cells/µl, rendering the host susceptible to OIs. These 
OIs or cancers eventually lead to death (36). 
 
1.1.5 Therapy 
 Six major classes of antiretroviral therapy (ART) currently exist, and they are 
designed to interfere with different stages of the HIV life-cycle. Entry inhibitors 
(CCR5 co-receptor antagonists) prevent the viral particle from binding to host-cell 
receptors. Fusion inhibitors inhibit the viral particle from fusing with the host-cell 
membrane. Non-nucleoside rt inhibitors (NNRTIs) inhibit rt from converting HIV-
RNA into cDNA, whereas nucleoside/nucleotide rt inhibitors (NRTIs) are faulty DNA 
building blocks which are inserted into a growing HIV DNA chain, resulting in DNA 
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chain termination as no additional nucleotides can be attached to them. Integrase 
inhibitors block HIV DNA integration into host DNA, whereas protease inhibitors 
prevent the cleavage of polyproteins needed to produce mature infectious virions. 
Multi-class combination products combine HIV drugs from two or more classes into a 
single product (41). ART was administered as mono or dual therapy before the advent 
of combination antiretroviral therapy (cART) (42). cART inhibits viral replication and 
reduces HIV-1 viremia below the limits of detection by most conventional testing 
methods (<50 RNA copies/ml) resulting in significant immune reconstitution (43). 
This also leads to dramatic reduction in the morbidity and mortality associated with 
HIV infection (44). However, cART is not a curative therapy for HIV infection and 
drug resistance leading to treatment failure has been documented for all classes of 
ART (45). 
 
1.1.6 Viral Persistence and the Immune Response 
  HIV persistence can be attributed to a high mutation rate of ~ 3 x 10-5 
mutations per nucleotide base for each cycle of replication, allowing the generation of 
a genetically diverse  population of (109 to 1010) virions within an infected host each 
day (46). A hybrid-virus can be generated through genetic recombination upon 
infection of a new host cell with multiple strains of HIV, which adds to the overall 
viral diversity (47). Viral mutations usually generate quasispecies including drug-
resistant and immune escape variants (48,49). Most HIV-infected individuals mount 
effective cellular and humoral immune responses in the first few months of infection. 
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However, these responses fail to contain viral replication over longer time periods. 
The scope of this thesis is limited to the role CD8+ T cell responses in HIV infection. 
 
1.2 CD8+ T Cells 
1.2.1 T Cell Selection 
 T cells are derived from bone marrow hematopoietic stem cells. Committed 
early immature T cell precursors journey through the bloodstream to the thymus. 
Thymocytes at this early stage are termed double-negative (DN) thymocytes as they 
do not express CD4 or CD8 molecules. These DN thymocytes are subdivided into four 
sequential stages of differentiation based on the surface expression of CD44 and 
CD25 molecules: DN1, CD44+CD25−; DN2, CD44+CD25+; DN3, CD44−CD25+; and 
DN4, CD44−CD25− (50). DN thymocytes have the potential to differentiate into γδ or 
αβ TCR-expressing cells (51). Cells that differentiate along the αβ TCR pathway 
begin to express the surrogate α chain (pre-TCR-α) encoded by a non-rearranging 
locus (52,53). The surrogate α chain pairs with the TCR β-chain, which was a product 
of recombination-activating gene (RAG)-mediated gene rearrangement (54,55). This 
pre-TCR-αβ-pair associates with CD3/ζ proteins to form a novel complex called the 
pre-TCR-complex that is important in proximal signal transduction (56). T cells 
emerging from the late DN3 and DN4 stages undergo extensive proliferation, while 
pre-TCR-α expression and TCR β-chain rearrangement ceases. The resultant mature 
αβ T cells express CD8 coreceptor proteins first, and then CD4 (51). Cells expressing 
both CD4 and CD8 molecules, termed double positive (DP) thymocytes, comprise 
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90% of immature αβ-TCR-expressing cells populating the lymphoid compartment in 
the thymus of young individuals. 
These small double-positive thymocytes undergo a thymic selection process 
which is characterized by death by neglect, negative selection, positive selection and 
lineage-specific development. Due to poor TCR-pMHC interaction, most DP 
thymocytes die by neglect. Thymocytes bearing TCRs with strong avidity for self-
peptides are potentially auto-reactive T cells and they undergo apoptotic cell-death 
upon TCR ligation with self-pMHC (negative selection). However, cells bearing 
TCRs that recognize self-peptides and generate signals below a certain threshold of 
avidity receive a survival signal (positive selection). These processes precede lineage 
specific differentiation into either CD4+ or CD8+ mature T cells. 
 
1.2.2 TCR Signaling 
Signaling through the TCR and costimulation via receptors such as CD28 are 
both essential for successful naïve T cell activation (57). TCR signaling is antigen-
specific, while costimulatory signals that are usually provided by professional antigen 
presenting cell (APC) are antigen-independent and serve to modulate the T cell 
response and survival. Once activated, T cells respond by producing cytokines that 
modulate other cells, undergo clonal expansion, differentiate into effector and memory 
T cells, and in the case of cytotoxic T lymphocyte (CTL), mediate killing (cell-
mediated cytotoxicity). However, a naïve T cell becomes unresponsive (anergic) and 
tolerant when exposed to antigen in the absence of a costimulatory (second) signal. 
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 There are two different TCR heterodimers, the α:β TCR and γ:δ TCR. About 
95% of peripheral T cells bear alpha (α) and beta (β) chain TCRs, while the remaining 
5% express gamma and delta (γ/δ) chains. Each chain of the αβ TCR is made up of a 
variable (Vα or Vβ) and a constant (Cα or Cβ) domain. The Vα is encoded by two DNA 
segments (Vα and Jα), while the Vβ is encoded by three segments (Vβ, Dβ, and Jβ). The 
αβ-TCR resembles the Fab fragment of the Ig molecule. Upon receptor engagement, 
the αβ heterodimer associates with the CD3 molecule (TCR-complex) to initiate signal 
transduction across the cell membrane and phosphorylation to activate downstream 
signaling pathways. TCR interaction with the MHC-peptide complex triggers 
phosphorylation of tyrosine residues on the immunoreceptor tyrosine-based activation 
motifs (ITAMs) of the CD3 α, δ, ε and ζ chains (58). Protein tyrosine kinases (PTKs) 
important in T cell activation are Lck and Fyn of the Src family and ZAP-70 of the 
Syk family. These PTKs interact with the ITAMs of the TCR-complex. Activation of 
Lck kinase is dependent on the protein tyrosine phosphatase (PTP) CD45, which 
dephosphorylates an inhibitory tyrosine in the cytoplasmic tail of Lck. Activated Lck 
phosphorylates the ITAMs present in the cytoplasmic tail of the CD3 chains, making 
it a docking site for ZAP-70. ZAP-70 binds to the phosphorylated ITAMs and is 
activated (phosphorylated) by Lck. The substrates for ZAP-70 are LAT (linker for 
activation of T cells), a transmembrane protein with a long cytoplasmic tail and SLP-
76 (59,60). Phosphorylated LAT then recruits a number of adaptor proteins such as 
phospholipase γ 1 (PLCγ1), growth factor receptor-bound protein 2 (GRB2) and 
phosphatidylinositol 3-kinase (PI3K), which are crucial to T cell activation. Binding 
of LAT with these adaptor proteins begins the process of gene transcription through 
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the NF-κB, NF-AT and STAT pathway (61-63). Genes coding for the growth factor 
IL-2, pro-inflammatory cytokines IFN-γ and TNF-α and antiapoptotic protein Bcl-xL 
are upregulated (64). SLP-76 helps stabilize and maintain the immunological synapse 
by promoting the activation and clustering of leukocyte function-associated antigen 
(LFA-1), an integrin molecule (65,66). 
 
1.2.3 T Cell Costimulation 
1.2.3.1 CD28/B7 Family 
Secondary signals affecting T cells can be stimulatory or inhibitory, and are 
mainly delivered by molecules belonging to the CD28/B7, tumor necrosis 
factor/tumor necrosis factor receptor (TNF/TNFR) superfamily and some chemokine 
receptors (67-69). CD28 and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) 
are well characterized receptors belonging to the CD28/B7 superfamily. CD28 
provides a stimulatory signal to T cells, while CTLA-4 provides an inhibitory signal to 
activated T cells (70,71). They are both type 1 transmembrane glycoprotein receptors 
with an MYPPPY motif essentially used for interacting with B7.1 (CD80) and B7.2 
(CD86) molecules expressed on APCs (72). CD28 is constitutively expressed on most 
T cells, and some plasma cells (73,74). CTLA-4 is constitutively expressed on 
regulatory T cells. CD28 is translocated to the immunological synapse in association 
with the TCR, SLP-76 and ZAP-70 kinase when ligated with either of B7.1 or B7.2 
(75,76). Lck kinase phosphorylates the YXXM motif in the cytoplasmic tail of CD28, 
which then becomes a docking site for the SH2-domains of Grb2 and PI3K (75). 
Phosphorylation of PI3K induces the production of phosphatidylinositol (3,4,5)-
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triphosphate (PIP3) from its substrate PIP2. This process enhances signal transduction 
and gene transcription through NFκB and NFAT pathways (77,78). CTLA-4 has 
stronger affinity for CD80 and CD86 than CD28, and signaling through this receptor 
tends to attenuate or terminate T cell responses (71,79), whereas signaling through 
CD28 prevents anergy in naïve T cells, and enhances IL-2 production, proliferation, 
and survival (64,70,80). Humans, however, acquire CD28−CD8+ T cells with age, a 
situation which is also observable in progressive HIV infection (81-83). 
Programmed death-1 [PD-1 (CD279)] is an inhibitory member of the CD28/B7 
superfamily that was originally cloned from a T cell hybridoma line exhibiting 
apoptosis (84). PD-1 is a 288 amino acid type 1 transmembrane protein with a 
cytoplasmic tail containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) 
and an immunoreceptor tyrosine-based switch motif (ITSM). In humans, PD-1 is 
encoded for by Pdcd1 gene on chromosome 2, and by Pdcd1 gene on chromosome 1 
in mice (85). Its expression on naïve T cells is extremely low, but it is inducibly 
expressed on activated T cells, B cells and myeloid cells (85). PD-1 interaction with 
any of its ligands PD-L1 [B7-H1, or CD274] or PD-L2 [B7-H2, B7-DC or CD273] 
dampens T cell responses by inhibiting membrane-proximal TCR signaling, 
downstream T cell proliferation, cytokine production and other effector functions (85-
88). However, PD-1-mediated inhibition can be overcome by strong TCR stimulation 
and CD28 costimulation (86,89). PD-L1 is constitutively expressed on mouse T and B 
cells, dendritic cells, macrophages, and mesenchymal stem cells, while PD-L2 is 
inducibly expressed on dendritic cells, macrophages and bone marrow-derived mast 
cells (90,91). The tyrosine motifs present in the cytoplasmic tail of PD-1 become 
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phosphorylated upon ligation. SH2-domain containing tyrosine phosphatase 1 (SHP-
1) and SHP-2 then binds to the ITIM and ITSM motifs of PD-1. This interaction 
downregulates TCR signaling and dephosphorylates other signaling intermediates 
(88). However, a mutation in the ITSM motif of PD-1 abrogates the inhibitory 
function of PD-1. This indicates that the ITSM alone plays the major role in PD-1-
mediated inhibition (88). PD-1 interaction with SHP-2 appears to be stronger than 
with SHP-1, meaning PD-1 functions by recruiting SHP-2, and perhaps SHP-1 to the 
TCR complex (92). CTLA-4 prevents Akt activation, while PD-1 inhibits Akt 
activation as well as PI3K activity. Also, PD-1 signaling inhibits the phosphorylation 
of ZAP-70, CD3ζ and PKCθ (93). Upon TCR ligation and T cell activation, CTLA-4 
is transported to the immunological synapse from an intracellular store depending on 
the signaling strength (94). PD-1 molecules are redistributed from uniform cell surface 
expression to concentrate at the immunological synapse upon TCR ligation (95). 
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Figure 1.4: PD-1 signaling pathway. PD-1 ligation by PD-L1 or PD-L2 causes the 
immediate phosphorylation of PD-1 cytoplasmic tyrosine residues ITIM and ITSM. 
SHP-2 molecules are recruited to the tyrosine residues and their association 
dephosphorylates molecules associated with signal transduction via the PI3K pathway 
with resultant inhibition of signaling through the Akt pathway. This process 
downregulates production of pro-inflammatory cytokines such IFN-γ, growth 
cytokines such as IL-2 and antiapoptotic molecules such as Bcl-xL. However, this 
inhibitory effect can be overcome by strong TCR stimulation and CD28 costimulation 
with resultant increase in cytokine production and enhanced cell survival. Reprinted 
by permission from Macmillan Publishers Ltd (85). 
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1.2.3.2 TNF/TNFR Family 
 The human homologue of 4-1BB was cloned in 1993 shortly after its discovery 
in mice (96,97). 4-1BB is a costimulatory molecule that is inducibly expressed on T 
cells upon activation, and constitutively expressed on APCs (98). Its ligand, 4-1BBL, 
is expressed on activated professional APCs, neurons, astrocytes, hematopoietic stem 
cells and myeloid progenitors (98-101). 4-1BBL expression on B cells and DC is 
mainly regulated by CD40 (99). The 4-1BB/4-1BBL interaction provides a 
costimulatory signal to T cells, although 4-1BB has a preferential effect on CD8+ T 
cells in antiviral and antitumor immunity in mice (102-104). Its importance in recall 
CD8+ T cell responses in viral infections and in maintenance of effector memory 
CD8+ T cells late in the primary immune response has been elucidated in mouse 
models (102,105-107). 4-1BB signals independently of CD28 costimulation in the 
presence of a strong TCR stimulation (107,108). Once bound to its ligand, 4-1BB 
recruits TNFR-associated factors (TRAFs) - TRAF1, TRAF2 and TRAF3, with 
downstream activation of NF-κB, c-Jun N-terminus kinase (JNK), extracellular signal 
regulated kinase (ERK) and p38 mitogen associated protein (MAP) kinase pathways 
(109-112). T cell survival is enhanced by 4-1BB through TRAF1 and ERK-dependent 
downregulation of the pro-apoptotic molecule Bim, and the NF-κB-dependent 
upregulation of antiapoptotic genes such as bcl-XL and bfl-1 (110,111,113,114). CD4+, 
CD8+, CD28+, and CD28- T cell cytokine production, proliferation and cytolytic 
effector functions can be enhanced by 4-1BB costimulation (115-119). 
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1.2.4 Antigen Processing and Presentation 
T cells recognize and afford protection against intracellular microbes (cell 
mediated immunity) that avoid humoral and complement-mediated attack in a two-
step process. Firstly, intracellular pathogens are broken down to smaller fragments 
(peptides) and loaded onto major histocompatibility complex (MHC) molecules 
(antigen processing). In the second step, the peptide-MHC (pMHC) complexes are 
transported to the cell surface where they can be easily recognized by an antigen-
specific T cell (antigen presentation). CD8+ T cells recognize peptides in association 
with MHC class I (MHC-I) molecules, whereas CD4+ T cells recognize peptides 
bound to MHC class II (MHC-II) molecules. 
Internalized or endogenous protein antigens in the cytosol are broken down by 
a large, multicatalytic protease complex called the proteasome. Transporter associated 
with antigen processing (TAP), a member of the ATP-binding cassette (ABC) family 
of transporters helps in the translocation of cytosolic generated peptides into the 
lumen of the endoplasmic reticulum where they are loaded on newly synthesized 
MHC-I molecules (120,121). The chaperone protein calnexin binds to newly 
synthesized MHC-I α chains in the ER and assists in protein folding as well as 
promotes assembly with β2-microglobulin (β2m). The partly folded MHC-I molecule 
is released from calnexin once it binds to β2m, and then it binds the peptide-loading 
complex (PLC) which is made up of TAP, calreticulin (CRT), TAP-associated protein 
(tapasin) and ERp57. Calreticulin carries out a similar chaperone function to calnexin. 
Tapasin performs a bridging function between MHC-I and TAP, recruiting MHC-I-
β2m dimers and calreticulin to the PLC (122,123). ERp57 is a thiol oxidoreductase 
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that assists in the folding of newly synthesized MHC-I α2 molecules in the ER (124). 
Endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), 
found in mice, is a luminal component that plays a crucial role in the generation of 
peptide MHC-I complexes (125). Its human homologues are termed endoplasmic 
reticulum aminopeptidase-1 (ERAP1) and ERAP2 (126,127). Peptides, usually 8-10 
amino acids in length, are loaded in the α1α2 domain of MHC-I, but TAP molecules 
can transport larger peptides into the ER. The amino termini of these peptides can be 
trimmed by ERAAP/ERAP1 to yield peptides of an appropriate length for MHC-I 
binding. Upregulation of ERAAP can also be induced by IFN-γ. Suboptimal, low-
affinity peptides do not cause the release of the MHC-I from the PLC. Binding of 
high-affinity peptide to the partly folded MHC-I may cause conformational changes 
that complete the folding of the MHC-I molecule and trigger its release from the PLC. 
The fully folded MHC-I loaded with an appropriate peptide can now be transported to 
the cell surface. Although hundreds to thousands of potentially generated peptides 
have appropriate sequence to bind MHC-I, the bulk of responding antiviral CTL 
population CD8+ T cells recognize a tiny fraction of potential epitopes; a phenomenon 
referred to as immunodominance (128-131). 
 
1.2.5 Peptide Recognition and Activation of CD8+ T Cells 
 CD8+ T cells only recognize peptides presented by self-MHC class I 
molecules. Peptides, usually 8 to 11-mer, that dominate the recognition events with a 
particular MHC-I allele are termed “immunodominant” epitopes, whereas less-
recognized peptides are termed subdominant (129,130). The peptide binding groove of 
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MHC-I is flanked on both sides by α-helices and has a floor of antiparallel β-strands 
(132). Anchor residues of peptides interact with allele-specific pockets in the peptide 
binding groove of MHC class I, making upward pointing amino acid side chains 
available for interaction with the TCR (133,134). MHC class I molecules constantly 
present self and pathogen-derived peptides, but most auto-reactive T cells are clonally 
deleted during thymic selection. Antigen-specific T cells recognize the foreign 
peptides presented by self-MHC class I and form a stronger supramolecular adhesion 
complex (SMAC) or immunological complex with the APC in order to activate the T 
cell. The immunological synapse is further stabilized by the CD8 co-receptor on CD8+ 
T cells (135). Initial T cell priming takes place in the secondary lymphoid organs such 
as lymph nodes and spleen. The process of signal transduction and activation of CD8+ 
T cells follows the TCR signaling process already discussed in 1.2.2 above. 
 CD8+ T cells can become effector cytotoxic T lymphocytes (CTL) upon 
activation. CTL mediate the killing of virus-infected and tumor cells through two 
dominant contact-dependent pathways, the Fas/Fas ligand pathway and 
perforin/granzyme pathway. These two pathways are not mutually exclusive as an 
individual CTL may be equipped with both killing options (136). The Fas/Fas ligand 
and perforin/granzyme pathways result in activation of a family of cytotoxic 
proteases, the caspases, within the target cell that mediate cell-death. The two 
pathways differ in how they activate the caspases. Contained in the lytic granules of a 
CTL are perforin, a Ca2+-dependent pore-forming protein similar to the C9 component 
of complement, and an array of cathepsin-like proteases that are collectively referred 
to as granzymes. Perforin molecules “perforate” the membrane of the target cell, 
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thereby, facilitating the entry of granzymes into target cells in a manner that is still 
much debated (137). Five different granzymes can be found in humans, but granzymes 
A and B predominate in human CTL and are each capable of proteolytically activating 
cell death pathways, which ultimately cause fragmentation of the target cell’s DNA 
(138,139). Caspase-8 is recruited to the cytoplasmic tail of the Fas receptor, via the 
adaptor protein Fas-Associated protein with Death Domain (FADD) upon ligation of 
Fas on the target cell with FasL on the CTL, moving the cell into apoptosis (140-142). 
Recruitment of caspase-8 to the receptor complex results in activation of this protease, 
which in turn amplifies downstream caspase activation, either directly (type I 
pathway) or indirectly by cleaving Bid and provoking cytochrome c release from 
mitochondria (type II pathway) that activates the Apaf - 1/caspase-  “apoptosome”.  
The apoptosome then promotes activation of downstream effector caspases that kill 
the cell (136,143). Eventual cell death could take between 1-7 hours and both the 
perforin-granzyme and Fas-FasL pathways contribute to this. The CTL detaches from 
the target cell and pursues another target cell as a “serial killer” upon the delivery of 
the “lethal hit” as the CTL escapes intact. This is achieved by the delivery of the lethal 
hit in immediate juxtaposition to the target cell membrane. 
While immunodominance can be beneficial in that it generates potent immune 
responses to resolve infections, and contributes to the memory T cell pool to promote 
rapid immune responses following re-infection; it can be unfavourable in HIV 
infection due to the high mutation rate of HIV (144). Mutation of the 
immunodominant epitope in HIV infection favours the emergence of escape variants 
that evade immune recognition (144). 
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1.2.6 Importance of Cytotoxic CD8+ T Cells (CTL) in Controlling 
HIV Infection 
CTL are potent effector cells of the adaptive immune response that function 
through direct recognition and killing of malignant cells or virus-infected cells. This is 
achieved either through the Fas-FasL pathway or the perforin-granzyme pathway, or 
through secretion of pro-inflammatory cytokines that can raise an antiviral state in 
neighboring cells (145). The importance of CD8+ T cells in controlling HIV infection 
has been well documented. Emergence of HIV-specific CD8+ T cells in primary HIV-
1 infection is associated with viremia containment to set-point levels (35,39). This is 
in turn accompanied by the generation of sequence mutations within immunodominant 
HIV-1 epitopes, thereby giving rise to CTL escape variants of the virus, which further 
confirms the selective immune pressure exerted by CTL on HIV-1 replication 
(37,146,147). The importance of CTL in containment of viremia was also observed in 
primary simian immunodeficiency virus (SIV) infection in rhesus macaque models 
(148). Further studies additionally showed that AIDS-related mortality fell and SIV 
set-point levels were significantly reduced by 2.4 log during vaccination with a T-cell 
based vaccine that induced potent and broad CTL responses (149). More importantly, 
enhanced control of viremia has been linked with the expression of particular class I 
human histocompatibility-linked leukocyte antigens (HLA) such as B*5701, B*51 and 
B*27 in humans (150,151)  and Mamu-B*08 in rhesus monkeys (152). 
Although the precise mode of action of these HIV-specific CD8+ T cells in 
containing HIV-1 infection is not fully understood, Wong et al. argued that the initial 
systemic suppression of SIV viremia by SIV-specific CD8+ T cells is achieved mainly 
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through non-cytopathic means (153). Investigators generally believe viral suppression 
is achieved through their ability to produce pro-inflammatory cytokines such as IFN-γ, 
TNF-α, growth factor IL-2, chemokine macrophage inflammatory protein-1β (MIP-
1β) and their ability to undergo clonal expansion upon activation and degranulate 
upon contact with target cells (154,155). However, progressive loss of CTL effector 
functions has been reported in HIV-1 infection, a phenomenon often referred to as 
“exhaustion”. 
 
1.2.7 CD8+ T Cell Exhaustion: characteristics and causes 
T cell exhaustion is a phenomenon characterized by hierarchical loss of 
antigen-specific T cell functions, which can ultimately result in clonal deletion. This T 
cell dysfunction is often reflected in a reduced ability to produce IL-2 and TNF-α, 
reduced proliferation, a reduction in cytotoxicity, and increased susceptibility to 
apoptosis relative to polyfunctional T cells (156). Exhausted T cells remain in a 
monofunctional, IFN-γ-producing state before undergoing clonal deletion (157). 
Exhaustion was first observed in chronic lymphocytic choriomeningitis virus (LCMV) 
infection in mice (158). It has since been reported in some cancers, hepatitis B virus 
(HBV), hepatitis C virus (HCV) and HIV-1 infections (159,160). Accumulation of 
dysfunctional T cells in progressive HIV-1 infection is also associated with skewed 
differentiation into an effector memory phenotype. Chemotaxis of effector memory 
cells is impaired with high viremia, thereby posing another challenge to controlling 
viral burden (161-163). 
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Studies revealed that viral persistence and loss of CD4+ T cell help in 
progressive HIV/SIV-infection significantly contribute to CTL exhaustion (164,165). 
A genome-wide microarray analysis carried out on exhausted CD8+ T cells in mice, 
chronically infected with LCMV, implicated members of the B7/CD28 and 
TNF/TNFR families, which are exclusively upregulated either individually or in 
combination, in development of exhaustion. Inhibitory receptors upregulated on 
exhausted LCMV-specific CD8+ T cell in chronic LCMV infection included CTLA-4, 
PD-1, lymphocyte-activation gene-3 (LAG-3), CD160, 2B4 (CD244), GP49 and 
paired-immunoglobulin like receptor B (PirB) relative to functional effector or 
memory cells (166,167). 
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Figure 1.5: T cell exhaustion. A naïve CD8+ T cell becomes primed by an antigen 
with supporting costimulation, and undergoes clonal expansion into effector CD8+ T 
cells which clear viremia. Some clones differentiate into highly polyfunctional 
memory CD8+ T cells which are capable of producing pro-inflammatory cytokines 
(TNF-α, IFN-γ, and IL-2), proliferate and are resistant to apoptosis. A number of these 
polyfunctional memory CD8+ T cells, however, become functionally impaired in a 
hierarchical manner as the primary infection progresses to a chronic phase and antigen 
persists. IL-2 production and proliferation are the first functions lost. Exhaustion 
become severe with increased viremia and reduced CD4+ T cell help and in some 
cases, these exhausted CD8+ T cells die by apoptosis (clonal deletion). Markers 
associated with T cell exhaustion include PD-1, LAG-3, 2B4, CD160. Excerpt from 
(159). 
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Inhibitory signals provided by LAG-3, once bound to its MHC-II ligand, 
attenuate T cell activation, proliferation, and renewal through cell cycle arrest (168-
170). Blockade of LAG-3 alone on LCMV-specific CD8+ T cells was not sufficient to 
reverse exhaustion or reduce viremia (171,172). 2B4 signaling on CD8+ T cells can 
either be activating or inhibitory (173). However, elevated expression of 2B4 has been 
shown to be inhibitory and contribute to HCV- and LCMV-specific CD8+ T cell 
exhaustion (171,174,175). Expression of CD160 on LCMV-specific CD8+ T cells and 
its coexpression with PD-1 on HIV-specific CD8+ T cells is a marker of disease 
progression, and also defines T cell subsets with advanced impairment (167,171,176). 
Blocking the interaction of CD160 with its ligand, herpes virus entry mediator 
(HVEM), enhances proliferation and cytokine production in “exhausted” 
cytomegalovirus (CMV)- and HIV-specific CD8+ T cells (176). Upregulation of PD-1 
in chronic HIV-1, HBV and HCV-infections in humans and SIV-infection in rhesus 
macaques has been linked to antigen-specific T cell dysfunction (164,177). Other 
negative regulators of T cell activation such as T cell immunoglobulin mucin-3 (Tim-
3) and CTLA-4 have also been implicated in HIV and HCV-specific CD4+ and CD8+ 
T cell functional impairment as the expression levels of these receptors correlated with 
failure to control viremia (165,178). Also, coexpression of multiple inhibitory 
molecules on cancer and HIV-specific CD8+ T cells defines subsets with advanced 
dysfunction (179,180). 
 A dramatic decline in the expression of these inhibitory molecules was 
observed in HIV-1 infected subjects treated with cART, although effector functions 
were not restored in HIV-specific CD8+ T cell upon successful treatment 
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(165,177,181). In vitro blockade of PD-1 and LAG-3 interaction with their ligands 
restored effector functions such as cytokine production, enhanced proliferation and 
reduced apoptosis (182). Blocking the interaction of PD-L1 with PD-1 in vivo also 
reduced SIV viremia in rhesus macaques and led to clearance of LCMV in mice, 
though restoration of T cell effector functions was only partial (182,183). 
 
1.3 Immunotherapeutic Vaccines against HIV 
Unlike prophylactic vaccines, which provide protection against invading 
pathogens for uninfected persons, therapeutic (treatment) vaccines are designed to 
modulate the ongoing immune response in unresolved infections or other chronic 
conditions. Most therapeutic vaccines are engineered to induce cell-mediated 
immunity rather than humoral immunity by enhancing existing, or generating new 
immune responses towards chronic pathogens or tumor antigens. 
While most HIV-infected individuals have strong initial CTL responses in the 
primary phase, chronic infection becomes established partly due to the selective 
immune pressure exerted on the virus by the HIV-specific CD8+ T cell (37). Viral 
persistence, partly due to inefficient recognition of HIV escape mutants, alters HIV-
specific CD8+ T cell immunodominance and could precede functional impairment of 
these HIV-specific T cells (184). 
Introduction of cART has dramatically reduced morbidity and mortality 
among individuals with chronic HIV infection (185). However, HIV-specific CD8+ T 
cell dysfunction persists through successful ART treatment (181). In spite of the 
improvement in HIV management, there is need for a life-time strict adherence in 
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order to maintain effective control. Also, the cost of ART, adverse drug effects and 
the risk of developing resistance are still problematic for many infected individuals. 
Furthermore, the annual economic burden posed by the HIV epidemic in both the 
developing and developed world has hindered economic growth. In fact, a recent 
study shows that for every 10 persons beginning ART, 16 are newly infected with 
HIV (186). This demonstrates the urgency of exploring other alternatives such as 
immune-based strategies, which will be economically important and reduce the 
requirement for “life-time cART adherence”. 
 The intent of a therapeutic vaccine is to induce a potent anti-HIV immune 
response or enhance the existing response by deliberate exposure to HIV antigens. 
Ideally, responses generated through this means should contain viral replication at 
undetectable levels – a situation found in a small population of HIV-infected ART-
naïve individuals (elite controllers) that do not rapidly progress towards AIDS. This 
phenomenon is termed natural “functional cure” (187). Several lines of evidence 
suggest that partial control of HIV replication could delay the need for initiation of 
cART in ART-naïve patients or allow “drug-holidays” in patients on cART. However, 
partial control of HIV replication might not have maximum clinical benefit because 
HIV-infected ART-naïve patients with high CD4+ cell counts still have higher chances 
of dying from non-AIDS-related diseases than the general population (188,189). Also, 
the early initiation of cART significantly improves HIV prognosis in comparison with 
delayed treatment (190). Furthermore, life expectancy has been greatly reduced in 
patients placed on “drug-holidays” with the intention of reducing untoward drug 
effects (191). It is, therefore, desirable for HIV therapeutic vaccines to completely 
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eradicate infection rather than achieve partial control, although most researchers 
believe complete viral clearance is impossible due to the virus’ ability to integrate into 
the genome and remain latent for decades (192). Nonetheless, if a therapeutic vaccine 
is able to partially contain viremia, this will be an important improvement and will 
justify further investigation into designing new candidate vaccines. 
Evidence of functional cure in the Berlin patient suggests that purging the HIV 
reservoir is possible (193,194). There are on-going clinical trials combining various 
approaches, such as therapeutic vaccination, gene therapy and cART to drive viral 
loads down to complete remission (195). There is currently no Food and Drug 
Administration (FDA) approved therapeutic vaccine for human use (192). Initial HIV 
vaccine candidates tested such as whole inactivated virus (REMUNE) or recombinant 
protein (gp120) were administered as prophylactic vaccines, and immune responses 
generated by these vaccines were disappointing (196,197). 
 
1.3.1 Applying Heteroclitic Peptides to Therapeutic Vaccination 
Although specific, TCR are able to interact with multiple peptide antigens 
(198). If each clone in the T cell repertoire could only recognize one cognate antigen 
and was non-cross-reactive, there would be limited T cell responses and the repertoire 
would have to be enormous. The number of T cells specific for a single antigenic 
determinant is small, and at least one T cell in a few thousand must respond to a 
foreign peptide in order to generate a substantial immune response (199). There is, 
therefore, some need for T cell cross-reactivity. Recent studies have suggested the 
ability of a TCR to recognize more than one peptide (200). We can, therefore, 
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potentially exploit the “cross-reactivity” of T cells to generate desired immune 
responses. 
 Heteroclitic peptides are sequence variants of native peptide epitopes that 
stimulate T cell responses superior to the native epitope. Heteroclitic peptides contain 
amino acid substitutions that can enhance peptide-binding affinity for human 
histocompatibility-linked leukocyte antigens (HLA) and/or improve TCR recognition 
(201,202). Evidence in several experimental systems suggests that heteroclitic 
peptides stimulate more potent immune responses against their respective native 
peptide epitope than the native peptide itself (202). Potentially heteroclitic variants 
have been previously generated using HLA-A2 and A3-restricted tumor-associated 
peptides (9mers and 10mers) and HLA-A2-restricted viral peptides including, HBV 
Pol.455 and HIV Pol.476 (both 9mers). Regardless of the native peptide epitope, 
variant epitopes showing heteroclitic activity had conservative or semiconservative 
amino acid (aa) substitutions only at positions 3, 5, or 7, and these heteroclitic 
epitopes elicited up to a 107-fold increase in T cell responses (203).  Evidence from 
X-ray crystallography-inferred 3-dimensional structure of HLA-A2 and A3 
pMHC:TCR complexes show that side chains of aa at positions 3, 5 and 7 in these 
MHC molecules interact directly with the complementarity determining region 3 
(CDR3) of the TCR α and β chains (204,205). A table of aa similarity scores proposed 
by Sette et al. was derived by averaging the rank coefficient score for tolerability of 
point mutations within a protein (Dayhoff PAM250), hydrophobicity (an average of 
Kyte/Doolittle and Fauchere/Pliska scales), and aa side chain volume (measured by 
H2O displacement) for each aa pair (203). We propose that candidate heteroclitic 
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variants of HIV native peptide epitopes can be generated in a similar manner as done 
by Sette et al. tested and incorporated into therapeutic HIV vaccines. 
 
1.4 Rationale for this Study 
 Chronic HIV-infection often leads to ineffective CD8+ T cell responses, in the 
form of reduced cytokine production, decreased proliferation and ultimately apoptosis 
of HIV-specific CD8+ T cells. Inhibitory signals elicited by some TCR co-receptor 
molecules such as PD-1 have been implicated in this functional impairment. We 
previously demonstrated that heteroclitic peptides enhance IFN-γ and IL-2 production 
by HIV-specific CD8+ T cells (206). This finding led to the exploration in this study of 
whether heteroclitic peptides also improve HIV-specific CD8+ T cell proliferation and 
reduce PD-1 expression. In the second part of this work, we tested the possibility that 
heteroclitic peptide stimulation in the presence of 4-1BB costimulation or absence of 
the inhibitory PD-1 pathway may further improve T cell responses elicited by 
heteroclitic peptides. 
Heteroclitic variant epitopes augmenting IL-2 and/or IFN-γ production by 
HIV-specific CD8+ T cells were initially identified by ELISPOT. We then measured 
heteroclitic peptide-driven proliferation and examined the effect of heteroclitic peptide 
stimulation on PD-1 expression by HIV-specific CD8+ T cells. Also, we investigated 
the effect of PD-1 signaling blockade or 4-1BBL costimulation on HIV-specific CD8+ 
T cells responding to heteroclitic peptide stimulation. 
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2.0 Materials and Methods 
2.1 Ethics Statement 
All study participants gave informed consent for whole blood collection and 
immunological studies. The study protocol was originally reviewed and approved by 
the Memorial University of Newfoundland Faculty of Medicine Human Investigation 
Committee and annual renewal is approved by the Newfoundland and Labrador 
Provincial Health Research Ethics Authority. 
 
2.2 Study Subjects 
 Whole blood samples from HIV-1-infected individuals (coded 1 to 288) and  
HIV-uninfected volunteers (coded 1000 and above) were obtained from attendees of 
the Newfoundland and Labrador Provincial HIV clinic and Faculty of Medicine 
personnel, Memorial University of Newfoundland, St. John’s, Canada respectively. 
Sera from the HIV-infected subjects had previously been tested for HIV-1 antibodies 
by ELISA and serostatus confirmed by Western blot. HIV-infected subjects 
underwent routine clinical assessment with CD4+ T cell counts and viral load 
performed at least once every six months. Most HIV-infected study subjects had 
achieved viral suppression with cART below clinical detection limits at the time of 
participation. 
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2.3 Peripheral Blood Mononuclear Cell (PBMC) Isolation 
 PBMC were isolated from 20 ml of fresh whole blood collected by forearm 
venipuncture into vacutainer tubes containing acid-citrate-dextrose (ACD) 
anticoagulant. Plasma was collected following centrifugation at 400g for 10 min at 
room temperature (RT), aliquotted immediately and stored at -80ºC. The packed cells 
and buffy coat were diluted to 2x the original blood volume with phosphate buffered 
saline (PBS) and 15 ml buffy coat / packed cell suspension was layered over 15 ml 
Ficoll-PaqueTM PLUS (GE Healthcare Biosciences AB, Uppsala, Sweden) gradient 
separation medium and centrifuged at 400g, for 30 min at RT, with no brake. PBMC, 
which are suspended between the plasma-Ficoll interface, were carefully transferred 
into a clean 50 ml tube and washed with PBS containing 1% fetal calf serum (FCS) 
(Invitrogen). After counting, PBMC were resuspended in complete lymphocyte 
medium (RPMI 1640 supplemented with 10% FCS, 100 μg/ml streptomycin, 100 
IU/ml penicillin, 2 mM L-glutamine, 10 mM HEPES buffer solution and 2 x 10-5 M 2-
mercaptoethanol; all from Invitrogen) and either used fresh or cryopreserved until 
needed. 
 
2.4 PBMC Cryopreservation and Thawing 
 Freshly isolated PBMC were resuspended in freezing medium [80% complete 
RPMI 1640 medium, 10% supplemental FCS and 10% dimethyl sulfoxide (DMSO)] 
at 10 x 106 cells/ml, transferred into 2 ml Nalgene® System 100™ cryovials (Thermo 
Fisher Scientific, Rochester, NY) and incubated overnight in Thermo Scientific™ Mr. 
Frosty™ freezing container at -80°C. PBMC were transferred to and maintained in the 
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liquid nitrogen (LN) tank after overnight incubation until required. To thaw cells, 
cryopreserved PBMC were immediately immersed in a 37°C water bath and gently 
agitated until the contents were almost completely thawed and then the contents were 
immediately transferred into a sterile 15 ml tube containing 10 ml complete medium, 
and washed three times to remove DMSO. Cells were resuspended in complete 
medium at 2 x 106 cells/ml and rested overnight at 37°C in a 5% CO2 incubator to 
allow for recovery. Cells were counted after overnight recovery and all PBMC used 
were > 50% viable by trypan blue exclusion. 
 
2.5 HLA Typing 
 Most participants enrolled in this study before September 2012 were fully 
typed for HLA class I A and B antigens with the Lambda Monoclonal Typing Tray 
Second HLA Class I, Lot #6A (One Lambda, Canoga, CA) as per manufacturer’s 
instructions. In order to maximize time while B cells are being transformed, newly 
enrolled participants expressing HLA-A2 were identified with HLA-A2 specific 
monoclonal antibody (NFLD.M2) (207), which was a kind gift from Dr. Sheila 
Drover’s Laboratory. Briefly, 1 x 105 PBMC were incubated with the primary A2-
specific-antibody at 4°C for 30 mins, washed and labelled with a secondary goat anti-
mouse IgG fluorescein isothiocyanate (FITC) fluorochrome-conjugated polyclonal 
antibody for HLA-A2 antigen detection. PBMC, not incubated with the HLA-A2 
specific monoclonal antibody, but stained with FITC-conjugated goat anti-mouse IgG 
served as a control. PBMC were then analysed by flow cytometry for HLA-A2 
expression. 
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2.6 Peptides 
 HIV peptide pools stimulating IFN-γ/IL-2 responses (Gag and Nef) by HIV-
specific CD8+ cells were identified by previous students. Peptides pools consisted of 
sequential overlapping 15mer peptide sets spanning the major HIV clade B antigens 
(National Institutes of Health AIDS Research and Reference Reagent Program). 
Peptide pools were deconvoluted with peptide matrices by ELISPOT as previously 
described (208) to identify individual 15mers responsible for the cytokine responses. 
Twenty-four potentially heteroclitic variants were synthesized from reference HLA-
A2-restricted, optimally defined 9mer HIV peptide epitopes stimulating IL-2 
production by HIV-specific CD8+ T cell from our HIV-infected study subjects. 
Conservative and semi-conservative aa substitutions were made at positions 3, 5 or 7 
of Nef 8391, Nef 135143, Gag 7785 and 3, 5 or 8 of Gag 433440. The 
choice of aa and position of substitution was made as described in section 1.3.1. The 
rarity or absence of aa at positions of interest in the Los Alamos HIV sequence 
database 
(http://www.hiv.lanl.gov/content/sequence/QUICK_ALIGN/QuickAlign.html) was 
also considered in selecting the appropriate aa for substitution. HIV peptides were 
synthesized by PEPTIDE 2.0. Inc., USA. Individual peptides were dissolved in 
DMSO at 10 mg/ml, and stock solutions of 1 mg/ml peptides in unsupplemented 
RPMI 1640 were aliquotted. The sequences of all reference peptides tested and their 
variants are shown in Table 2.1. 
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Table 2.1: Reference and corresponding variant peptide sequences 
 
Reference Peptide 
(name, position: aa sequence) 
Variant Peptides 
(name: aa sequence) 
 
 
A2-7 (Nef83): AAVDLSHFL 
A2-7-1:   AALDLSHFL 
A2-7-2:   AATDLSHFL 
A2-7-3:   AAVDISHFL 
A2-7-4:   AAVDVSHFL 
A2-7-5:   AAVDLSQFL 
A2-7-6:   AAVDLSRFL 
 
 
A2-8 (Nef135): YPLTFGWCF 
 
A2-8-1:   YPITFGWCF 
A2-8-2:   YPVTFGWCF 
A2-8-3:   YPLTYGWCF 
A2-8-4:   YPLTWGWCF 
A2-8-5:   YPLTFGFCF 
A2-8-6:   YPLTFGRCF 
 
 
A2-Gag (Gag77): SLYNTVATL 
 
A2-Gag-1:   SLWNTVATL 
A2-Gag-2:   SLLNTVATL 
A2-Gag-3:   SLYNSVATL 
A2-Gag-4:   SLYNWVATL 
A2-Gag-5:   SLYNTVGTL 
A2-Gag-6:   SLYNTVMTL 
 
 
A2-9 (Gag433): FLGKIWPS 
 
A2-9-1:   FLSKIWPS 
A2-9-2:   FLNKIWPS 
A2-9-3:   FLGKTWPS 
A2-9-4:   FLGKKIWPS 
A2-9-5:   FLGKIWPV 
A2-9-6:   FLGKIWPVS 
AA substitution made are highlighted in red and underlined 
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2.7 ELISPOT Assay to Measure Peptide-specific IFN-γ and 
IL-2 Production by HIV-specific CD8+ T Cells 
The polyvinylidene difluoride (PVDF) membranes of MultiScreen 96-well 
microtitre plates were activated by wetting with 15 µl/well of 35% ethanol, and 
washed four times with PBS. The plates were coated with 100 µL 7.5 µg/ml IFN-γ 
mAb 1-D1K or 15 µg/ml IL-2 mAb IL2-1/249 (Mabtech, USA), and incubated 
overnight at 4°C.  Plates were washed four times with PBS and blocked with 150 µL 
of PBS containing 1% FCS for 2 hrs at 37°C. Fresh or thawed PBMC rested overnight 
were counted and their viability determined by trypan blue exclusion. PBMC at a 
concentration of 2 x 106 cells/ml of complete RPMI 1640 medium were plated at 2 x 
105 cells/well in duplicate for IFN-γ or 4 x 105 cells/well singly for IL-2 respectively. 
Cells in individual wells were stimulated with 4 µg/ml peptides. Unstimulated PBMC 
served as a negative control while cells stimulated with 4 µg/ml phytohemagglutinin 
(PHA) served as a positive control. The plates were washed four times with PBS after 
overnight incubation at 37ºC in a 5% CO2 incubator. 100 µl/well of 1 µg/ml 
biotinylated anti-IFN-γ mAb 7-B6-1 or anti-IL-2 mAb IL-2-II (Mabtech) detection 
antibody were added and incubated for 2 hrs at RT. Plates were washed again four 
more times with PBS and 100 µl/well of streptavidin-alkaline phosphatase conjugate 
(ALP) (Mabtech), diluted 1:1000 in PBS supplemented with 0.5% FCS was added for 
1 hr. Wells were washed again four times with PBS, and 100 µl/well of a 1/100 
diluted chromogenic ALP substrate (Bio-Rad Laboratories, Hercules, CA) in colour 
development solution was added. The plates were incubated with the substrate at RT 
for 20 mins – 1 hr until the emergence of dark-purple spots. Colour development was 
42 
 
stopped by rinsing the plates with tap water. Plates were air-dried overnight and spots 
were counted with an ImmunoScan ELISPOT reader (Cellular Technology Ltd., 
Cleveland, OH). Each spot represents a cytokine-producing cell. Wells producing 
twice the background spots and at least 50 IL-2 spot forming units (SFU)/106 PBMC 
or 100 IFN-γ SFU/106 PBMC were considered indicative of a positive response to 
peptide stimulation. 
 
2.8 Proliferation Assays and Assessment of PD-1 
Expression on Dividing CD8+ T Cells 
CellTraceTM carboxyfluorescein succinimidyl ester (CFSE) Cell Proliferation 
Kits (Invitrogen, Oregon, USA) were utilized in the proliferation assays. The CFSE 
dye was purchased from the manufacturer in the diacetylated form, 
carboxyfluorescein diacetate N-succinimidyl ester (CFDA, SE). The diacetate group 
of the CFDA, SE makes the dye highly membrane permeant. The intracellular 
esterases cleave the diacetate group from the CFDA, SE to form CFSE. This makes 
the CFSE more fluorescent and less membrane permeable. The amino-reactive 
succinimidyl side chains of the CFSE dye then covalently couple the dye to 
intracellular proteins, thus making the cells almost permanently fluorescent. CFSE 
was used to monitor lymphocyte division based on the sequential halving of the 
fluorescent intensity of the daughter cells. PBMC were either used fresh or thawed 
and rested overnight at 37°C. PBMC resuspended at 1 x 106 cells/ml in PBS 
supplemented with 5 mM ethylenediaminetetraacetic acid (EDTA) (Sigma) and 0.25 
μM CFSE were incubated in the dark at 37ºC for 10 min. Staining was quenched by 
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adding 5 volumes of ice-cold lymphocyte media and the cells incubated on ice for 5 
min. Cells were pelleted by centrifugation, and washed three times with complete 
lymphocyte medium. Staining was confirmed with a fluorescent microscope. PBMC 
were then resuspended at 2 x 106 cells/100μl lymphocyte medium, and stimulated for 
1 hr at 37°C with 100 μl of peptide at 200 μg/ml for a final peptide concentration of 
100 μg/ml, resuspended at 1 x 106 cells/ml in complete lymphocyte medium and 
maintained in culture for 7 days at 37ºC in a 5% CO2 incubator. For proliferation 
assays with immunomodulating agents, cells were resuspended in complete 
lymphocyte medium supplemented with either 500 ng/ml of 4-1BBL fusion protein 
(R&D Systems, USA) or 10 µg/ml of anti-PD-1 (PD-1.3.1; Miltenyi Biotec Inc., 
USA). Cells were harvested on day 7 and stained with a two color panel for surface 
markers using anti-CD8-PerCP (BW135/80; MiltenyiBiotec) and anti-PD-1-APC 
(EH12.2H7; BioLegend). Staining was performed according to manufacturer’s 
instructions with the use of appropriate isotype controls. Briefly, cells were washed 
with PBS supplemented with 5 mM EDTA, 0.5% FCS, 0.2% sodium azide (Sigma), 
pH adjusted to 7 – 7.2 (flow buffer); and then incubated with anti-CD8-PerCP and 
anti-PD-1-APC at 4°C for 20 min. Cells were washed again with flow buffer and 
resuspended in 1% paraformaldehyde. 1 x 105 events (cells) were acquired for 
analysis within one week of staining with a FACSCaliburTM Cell Analyzer (BD 
Biosciences). Data was analyzed using WINMDI 2.8 software. 
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2.9 Statistical Analysis 
All statistical analyses were performed using the GraphPad Prism (version 4.0) 
statistical software package (Graph-Pad Software, San Diego, CA). Normal 
distribution of data was assessed by the Kolmogorov-Smirnov test and non-parametric 
testing done for comparisons. Statistical significance (p value) of the effect of 
heteroclitic peptide stimulation on PD-1 expression was calculated by using Wilcoxon 
signed-rank test. A p value < 0.05 was considered statistically significant. Correlation 
between lower PD-1 expression and increased proliferation was assessed by linear 
regression analysis. 
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3.0 Results 
3.1 Heteroclitic Peptide Identification 
 Our laboratory previously demonstrated that heteroclitic peptides can enhance 
IFN-γ and IL-2 production by HIV-specific CD8+ T cells (206). In this study, we first 
identified additional heteroclitic peptides by ELISPOT assay. PBMC from over 80 
HIV-infected individuals were screened in duplicate for IFN-γ or in single test for IL-
2 production by HIV-specific CD8+ T cells responding to one or more of the four 
peptide sets used in this study (Table 2.1). All peptides were 9mers except A2-9 and 
variants A2-9-1, A2-9-2, A2-9-3, and A2-9-5, which are 8mers. Heteroclitic peptides 
were selected based on previously described criteria. Briefly, after background 
subtraction, variant peptides that stimulated ≥ 100 more IFN-γ SFU/106 PBMC or ≥ 
50 more IL-2 SFU/106 PBMC than the corresponding reference peptides were 
considered heteroclitic, provided that the total SFU/106 PBMC was ≤ 1000 for IFN-γ 
or ≤ 500 for IL-2. In the case of responses ≥ 1000 IFN-γ SFU/106 PBMC or ≥ 500 IL-
2 SFU/106 PBMC, variant peptides were considered heteroclitic when they stimulated 
≥ 10% more IFN-γ or IL-2 SFU/106 PBMC than the reference peptide (206). PBMC 
from 25 subjects with a positive response to one or more of the reference peptides 
were further tested with their respective variants by ELISPOT assays (Table 3.1). 
Using the criteria above, we identified 29 heteroclitic peptides with PBMC from 9/25 
tested subjects (Table 3.2). Most of the heteroclitic peptides identified augmented 
IFN-γ production by HIV-specific CD8+ T cells, which didn’t always correlate with 
IL-2 responses (representative example is shown in Figure 3.1.A). This was the 
common trend observed with cytokine responses induced by the variant peptides 
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tested in our cohort. However, there were instances (A representative example is 
shown in Figure 3.1.B) where heteroclitic peptides enhanced both IFN-γ and IL-2 
responses. 
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Table 3.1: Number of subjects with positive IFN-γ and/or IL-2 responses against one 
or more peptides in each set 
 
Peptide Set A2-7 A2-8 A2-9 A2-Gag 
Fraction of 
tested subjects 
with  
IFN-γ 
responses 
 
 
10/25 
 
 
14/25 
 
 
12/25 
 
 
13/25 
Fraction of 
tested subjects 
with  
IL-2 responses 
 
1/14 
 
3/14 
 
6/14 
 
2/14 
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Figure 3.1: Representative cytokine expression patterns of HIV-specific CD8+ T 
cells stimulated with reference or variant peptides in ELISPOT assays. (A) 
Representative case of no association between IFN-γ production and IL-2 responses. 
(B) Representative case where heteroclitic peptide enhanced both IFN-γ and IL-2 
production. 
 
 
 
B 
A 
Heteroclitic peptides 
Heteroclitic peptides 
Subject 78 Subject 78 
Subject 35 Subject 35 
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3.2 Heteroclitic Peptide Stimulation Resulted in Enhanced 
HIV-specific CD8+ T Cell Proliferation 
To follow up on our finding that heteroclitic variants of HIV peptides enhance 
IFN-γ and IL-2 production by HIV-specific CD8+ T cells, we investigated whether 
they also enhance CD8+ T cell proliferation. PBMC from nine HIV-infected subjects 
previously identified with strong IFN-γ and/or IL-2 responses against heteroclitic 
peptides by ELISPOT assay were labeled with CFSE, stimulated with reference or 
heteroclitic peptides, and then left in culture for seven days. Cells were harvested on 
day 7, labeled with anti-CD8 and anti-PD-1, and analysed by flow cytometry. Twenty-
nine previously identified heteroclitic peptides were tested in proliferation assays in 
comparison to their respective reference peptides. Heteroclitic peptides enhanced IFN-
γ production in the majority of the cases selected for proliferation testing, except cases 
A2-9-3; #45, A2-9-6; #45, and A2-8-6; #78, where both IFN-γ and IL-2 production 
were enhanced (Table 3.2). We measured proliferation based on the fluorescence 
intensity of the dividing cells as the parental population remains CFSEbright, while 
fluorescence reduces with each subsequent generation of cells (CFSEdim). Only cases 
where either reference or heteroclitic peptides drove more than 0.5% absolute CD8+ T 
cell proliferation were considered for comparison. Proliferation was considered 
enhanced when heteroclitic peptides caused a > 20% increase in the percentage of 
proliferating CD8+ T cells relative to the reference peptides. Heteroclitic peptides 
enhanced total CD8+ T cell proliferation in 13/29 cases (Figure 3.2), and induced 
similar CD8+ T cell proliferation with reference peptides in 7/29 cases (Figure 3.3). 
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This demonstrates that heteroclitic peptides stimulated equivalent or greater CD8+ T 
cell proliferation than reference peptides in 20/29 cases. 
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Figure 3.2: Comparison of CD8+ T cell proliferation induced by reference or 
heteroclitic peptides I. PBMC from study participants were CFSE labeled and 
stimulated with reference or heteroclitic peptides in 7 day culture. CD8+ T cells were 
gated for analysis and results plotted as PD-1 vs. CFSE. Numbers in the quadrants 
indicate the percentage increase in the proliferating CD8+ T cells stimulated with 
heteroclitic peptides relative to reference peptides. The amino acid substitution made 
in the heteroclitic peptide sequence is highlighted in red and underlined above the 
plots. Results on PD-1 expression are discussed in section 3.3. 
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Figure 3.3: Comparison of CD8+ T cell proliferation induced by reference or 
heteroclitic peptides II. PBMC from study participants were CFSE labeled and 
stimulated with reference or heteroclitic peptides in 7 day culture. CD8+ T cells were 
gated for analysis and results plotted as PD-1 vs. CFSE. Numbers in the quadrants 
indicate the percentage increase in the proliferating CD8+ T cells stimulated with 
heteroclitic peptides relative to reference peptides. The amino acid substitution made 
in the heteroclitic peptide sequence is highlighted in red and underlined above the 
plots. Results on PD-1 expression are discussed in section 3.3. 
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3.3 Heteroclitic Peptide Induced Lower PD-1 Expression 
on Proliferating HIV-specific CD8+ T Cells 
Elevated expression of PD-1 on HIV-specific CD8+ T cells in chronic HIV 
infection has been linked to their dysfunction. This compelled us to investigate the 
level of PD-1 expression on proliferating CD8+ T cells stimulated with reference or 
heteroclitic peptides. PBMC from nine HIV-infected subjects previously identified 
with heteroclitic responses to variant peptides in ELISPOT assay were labeled with 
CFSE, stimulated with reference or heteroclitic peptides and then left in culture for 
seven days. Cells were harvested on day 7, labeled with anti-CD8 and anti-PD-1 and 
analysed by flow cytometry. Twenty-nine cases of previously identified heteroclitic 
peptides were tested in proliferation assays in comparison to their respective reference 
peptides. The median percentage of proliferating CD8+ T cells expressing PD-1 in the 
group stimulated with reference peptides was significantly higher than in the group 
stimulated with heteroclitic peptides [Figure 3.4; median PD-1hi CFSEdim CD8+ T cells 
29% with interquartile range (IQR) 19.5% – 79.5% in the reference peptide stimulated 
group versus 25%, IQR 17.5% – 64.5% on CD8+ T cells stimulated with heteroclitic 
peptides, n=29, p value = 0.005 (Wilcoxon signed-rank test)]. The level of PD-1 
expression in the CFSEbright CD8+ T cells was < 2% (range 0 – 1.6%) when stimulated 
with either reference or heteroclitic peptides. There was lower PD-1 expression on 
proliferating CD8+ T cells (15% - 88%) in response to heteroclitic peptide stimulation 
in 13/29 cases relative to reference peptide stimulation (Figure 3.5). 
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Figure 3.4: The frequency of PD-1hi CFSEdim CD8+ T cells responding to 
reference or heteroclitic peptide stimulation. In paired analysis of 29 cases, 
stimulation with reference peptides was compared to stimulation with heteroclitic 
peptides. The median percentage of PD-1hi CFSEdim CD8+ T cells was significantly 
higher with reference peptide stimulation than heteroclitic peptide stimulation 
(Wilcoxon signed-rank test). 
 
 
 
 
 
 
61 
 
 
 
 
         
 
        
 
        
 
Reference-Stimulated Heteroclitic-Stimulated 
#78       AAVDLSHFL 
#233       FLGKIWPVS* #233       FLGKIWPS 
#233       AAVDVSHFL* #233       AAVDLSHFL 
#78       AAVDVSHFL 
26.7 % 
29 % 
20 % 
CFSE 
PD-1 
A1 A2 
B2 
C1 
B1 
C2 
62 
 
 
 
 
        
 
      
 
        
  
 
#233       YPLTYGWCF 
 
#43       YPLTYGWCF 
#233       YPLTFGWCF 
#43       YPLTFGWCF 
#233       YPLTFGWCF #233       YPVTFGWCF 
 
33.3 % 
45.3 % 
53 % 
CFSE 
PD-1 
Reference-Stimulated Heteroclitic-Stimulated 
D1 D2 
E1 E2 
F1 F2 
63 
 
 
 
 
 
           
 
           
 
        
 
 
#233       YPLTFGWCF #233       YPLTFGRCF 
#35       YPLTFGWCF 
#78       FLGKIWPS 
#35       YPLTFGRCF* 
 
#78       FLNKIWPS 
16.2 % 
16.6 % 
36.6 % 
CFSE 
PD-1 
Reference-Stimulated Heteroclitic-Stimulated 
G1 G2 
H1 
I1 
H2 
I2 
64 
 
 
 
 
 
 
 
 
       
 
 
 
       
 
 
 
     
 
 
#43       FLGKIWPS 
#277       FLGKIWPS 
#43       FLGKTWPS* 
#277       FLNKIWPS 
#125       SLYNSVATL* #125       SLYNTVATL 
66.8 % 
25 % 
88.3 % 
PD-1 
Reference-Stimulated Heteroclitic-Stimulated 
CFSE 
J1 J2 
K1 K2 
L1 L2 
65 
 
 
 
 
 
 
 
 
 
         
 
 
Figure 3.5: Comparison of PD-1 expression on proliferating CD8+ T cells 
stimulated with reference or heteroclitic peptides. PBMC from study participants 
were CFSE labeled and stimulated with reference or heteroclitic peptide in 7 day 
culture. CD8+ T cells were gated for analysis, and results plotted as PD-1 vs. CFSE. 
Numbers in the quadrants indicate the percentage reduction in PD-1 expression on 
proliferating CD8+ T cells stimulated with heteroclitic peptides relative to reference 
peptides. The amino acid substitution made in the heteroclitic peptide sequence is 
highlighted in red and underlined. Variants enhancing proliferation and lower PD-1 
expression are marked with asterisks. 
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3.4 Correlation between Enhanced CD8+ T Cell 
Proliferation and Lower PD-1 Expression in Response to 
Heteroclitic Peptides 
T cell “exhaustion” is a collective term used to describe one or more different 
T cell functional impairments, which could range from defective cytokine production 
or proliferation to clonal deletion. Studies have shown a relationship between 
sustained upregulation of PD-1 and the reduced capacity of HIV-specific CD8+ T cells 
to proliferate. We investigated whether there was a relationship between lower PD-1 
expression and enhanced proliferation in CD8+ T cell populations responding to 
heteroclitic peptide stimulation. CFSE labelled PBMC were stimulated with reference 
or heteroclitic peptides in a 7 day proliferation assay. Cells were harvested on day 7 
and stained with fluorochrome-conjugated antibodies against CD8 and PD-1, and 
analysed by flow cytometry. We measured the percentage of proliferating CD8+ T 
cells expressing PD-1 in response to reference or heteroclitic peptides and found no 
significant correlation between enhanced proliferation and lower PD-1 expression on 
CD8+ T cells stimulated with heteroclitic peptides (Figure 3.6.C). However, 
heteroclitic peptides either induced lower PD-1 expression or enhanced proliferation 
in 21/29 cases. Also, heteroclitic peptide stimulation enhanced proliferation and lower 
PD-1 expression in 6/29 cases (Figure 3.5: B2; C2; G2; J2; L2 and M2). Identified 
heteroclitic peptides and their effects on HIV-specific CD8+ T cell proliferation and 
PD-1 expression is summarised in table 3.2. These data suggest that heteroclitic 
peptide stimulation exerts differential effects on responding CD8+ T cells. 
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Table 3.2: Effects of heteroclitic peptides on HIV-specific CD8+ T cell cytokine 
production, proliferation and PD-1 expression. 
  
Subject 
 
Peptide 
 
IFN-γ 
SFU/106 
PBMC 
 
IL-2 SFU/106 
PBMC 
 
apercent 
proliferation 
 
bpercent 
PD-1 
expression 
35 A2-8 843 60 0.8 100 
 A2-8-5 938 c110 2.9 100 
 A2-8-6 1088 15 2.4 83 
 A2-9 1005 25 0.1 100 
 A2-9-6 1325 50 0.6 83 
43 A2-8 1383 ND 2.4 71 
 A2-8-3 1563 ND 0.6 33 
 A2-9 1460 ND 2.2 59 
 A2-9-3 1770 ND 2.9 7 
45 A2-8 2123 15 0.5 0 
 A2-8-5 2363 30 6.0 0 
 A2-8-6 2350 55 0.7 0 
 A2-9 1878 15 15.2 88 
 A2-9-3 2300 100 2.8 86 
 A2-9-6 2258 80 20.5 0 
 A2-Gag 2208 95 8.4 88 
 A2-Gag-4 2488 35 4.7 85 
78 A2-7 1385 100 4.4 75 
 A2-7-4 1713 115 1.4 60 
 A2-8 1773 145 2.3 83 
 A2-8-6 2053 215 2.6 69 
125 A2-Gag 58 10 0.5 80 
 A2-Gag-3 35 80 0.7 28 
214 A2-Gag 250 0 3.4 29 
 A2-Gag-2 555 0 4.0 40 
 A2-Gag-4 353 0 3.8 34 
233 A2-7 500 ND 1.1 27 
 A2-7-1 705 ND 1.6 25 
 A2-7-4 858 ND 1.5 20 
 A2-7-5 813 ND 1.4 28 
 A2-7-6 930 ND 3.6 19 
 A2-8 998 ND 1.8 33 
 A2-8-2 1370 ND 1.1 18 
 A2-8-3 1098 ND 0.9 22 
 A2-8-6 1100 ND 1.9 21 
244 A2-7 868 0 1.0 10 
 A2-7-1 1003 15 1.5 13 
 A2-9 833 10 1.2 8.4 
 A2-9-2 958 5 1.3 7.7 
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 A2-Gag 698 5 2.4 79 
 A2-Gag-2 1400 10 2.3 78 
277 A2-8 788 13 2.1 14 
 A2-8-2 908 0 2.4 17 
 A2-9 465 13 3.3 24 
 A2-9-2 583 3 2.8 18 
 A2-9-5 618 3 2.3 22 
 A2-Gag 638 20 2.7 15 
 A2-Gag-2 768 3 3.2 25 
 
 
aPercent proliferation represents the percentage of total CD8+ T lymphocytes that 
proliferated over 7 days of stimulation with the indicated peptide.   
 
bPercent PD-1 expression represents the percentage of the CD8+ T cells that 
proliferated over 7 days of stimulation with the indicated peptide that express PD-1.   
 
cNumbers in bold text denote cases where either cytokine production or proliferation 
was increased or PD-1 expression reduced by the indicated (heteroclitic) peptide 
relative to the reference peptide. 
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Figure 3.6: Enhanced proliferation is independent of reduced PD-1 expression. 
(A) Scatter plot showing cases where heteroclitic peptides stimulation enhanced CD8+ 
T cell proliferation by > 20% (n=13). (B) Scatter plot showing cases where 
heteroclitic peptides stimulation induced lower PD-1 expression on proliferating CD8+ 
T cell by > 15% (n=13). (C) Correlation between enhanced CD8+ T cell proliferation 
and lower PD-1 expression. 
Cut-off Cut-off 
B 
C 
A 
R2 = 0.0220 
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3.5 Blockade of PD-1 or Costimulation with 4-1BBL 
Enhanced HIV-specific CD8+ T Cell Responses to 
Heteroclitic Peptides 
Studies have previously shown that blocking the PD-1 inhibitory pathway or 
providing costimulation via the 4-1BB signaling pathway can improve HIV-specific 
CD8+ T cell responses (177,209). These studies were carried out on memory CD8+ T 
cells using wild-type HIV peptides. We tested whether blocking the PD-1/PD-L1/2 
pathway during HIV-specific CD8+ T cell stimulation with heteroclitic peptides or 
delivery of 4-1BB costimulatory signal would further improve responding T cell 
effector function and reduce exhaustion. CFSE-labeled PBMC from HIV-infected 
subjects were stimulated with reference or heteroclitic peptides in a 7 day proliferation 
assay in the presence or absence of anti-PD-1 blocking antibody or 4-1BBL fusion 
protein. The percentage of CFSEdim CD8+ T cells was compared between PBMC 
populations that were treated with anti-PD-1 blocking antibody or no blocking 
antibody. We also compared PBMC populations that were cultured with or without 4-
1BBL fusion protein. Figure 3.7.A shows representative flow cytometry data where 
PD-1 inhibition enhanced proliferation of CD8+ T cells stimulated with reference 
peptide by 160%. Alternatively, 4-1BBL costimulation resulted in enhanced 
proliferation of CD8+ T cells by 40% (Figure 3.7.B). It is, however, worthy of note 
that 4-1BBL costimulation did not induce lower PD-1 expression on proliferating 
CD8+ T cells stimulated with reference peptide. The combined blockade of PD-1 and 
4-1BBL costimulation enhanced CD8+ T cell proliferation by 280%, which suggests 
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an additive effect on the responding cells (Figure 3.7.C). On the other hand, blocking 
the PD-1 pathway enhanced proliferation of CD8+ T cells stimulated with heteroclitic 
peptides by 78% (Figure 3.8.A). Also, 4-1BBL costimulation enhanced proliferation 
of CD8+ T cell responding to heteroclitic peptide by 56%, and lowered PD-1 
expression by 36% (Figure 3.8.B). These preliminary results demonstrate that 
treatment with immunomodulating agents such as anti-PD-1 or 4-1BBL can further 
boost T cell responses to heteroclitic peptides. 
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Figure 3.7: PD-1 blockade and / or 4-1BBL costimulation alters HIV-specific 
CD8+ T cell proliferation. (A) Representative flow cytometry data showing the 
CFSE profile of CD8+ T cells responding to reference peptide stimulation in the 
presence or absence of PD-1 blocking antibody. (B) CFSE profile of CD8+ T cells 
responding to reference peptide stimulation in the presence or absence of 4-1BBL 
costimulation. (C) CFSE profile of CD8+ T cells responding to reference peptide 
stimulation in the presence or absence of both anti-PD-1 blocking and 4-1BBL fusion 
protein. 
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Figure 3.8: PD-1 blockade or 4-1BBL costimulation alters HIV-specific CD8+ T 
cell proliferation. (A) Representative flow cytometry data showing the CFSE profile 
of CD8+ T cells responding to heteroclitic peptide stimulation in the presence or 
absence of PD-1 blocking antibody. (B) CFSE profile of CD8+ T cells responding to 
heteroclitic peptide stimulation in the presence or absence of 4-1BBL costimulation. 
Percentage increase in CD8+ T cell proliferation and percentage decrease in PD-1 
expression are shown in upper-left quadrants and lower-left quadrants respectively. 
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4.0 Discussion 
Different strategies are being explored to develop prophylactic and therapeutic 
approaches to prevent HIV infection and AIDS. One key strategy is to develop an 
HIV immunotherapy utilizing HIV-specific CD8+ T cells. Activation of HIV-specific 
CD8+ T cells following acute HIV infection contributes to the decline of viremia and 
delays disease progression (35,39). Also, HIV-specific CD8+ CTL persist through 
disease progression and are resistant to HIV infection since they do not express CD4, 
which is the main receptor for HIV entry and cellular infection. However, continuous 
stimulation via their TCR with HIV peptide epitopes during chronic HIV-infection has 
been implicated in their functional impairment, which persists even through successful 
ART and antigen withdrawal (181,184). The collection of T cell functional 
impairments that scientists have termed “T cell exhaustion” ranges from a partial 
decrease or loss of cytokine production through to clonal deletion (159). We 
previously demonstrated that heteroclitic peptide stimulation enhances cytokine 
production by HIV-specific CD8+ T cells (206). In this study, we investigated the 
effect on other T cell functional impairments by stimulating HIV-specific CD8+ T 
cells with heteroclitic variants of native HIV peptides. 
The process of T cell functional impairment appears stepwise and progressive in 
nature with antigen-specific proliferation being an effector function that is 
extinguished early. This study, therefore, aimed to characterize the effects of 
heteroclitic peptide stimulation on proliferation of HIV-specific CD8+ T cells. We first 
identified HIV variant peptides that enhanced HIV-specific CD8+ T cell cytokine 
responses by ELISPOT assays, and termed these variants “heteroclitic”. Most of the 
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identified heteroclitic peptides enhanced IFN-γ production, although some enhanced 
IL-2 production as well. Similar enhanced IL-2 responses have been reported by 
stimulation with an heteroclitic influenza virus peptide (A2-Flu-1) relative to the 
reference peptide (206). However, no systematic comparison of the frequency of 
heteroclitic peptides related to HIV epitopes versus other viral epitopes has been 
carried out. In this study, IFN-γ and IL-2 production were independently enhanced as 
there was no direct correlation between these two cytokine responses when PBMC 
were stimulated with heteroclitic peptides. 
Together with reduced cytokine production, loss of proliferative capacity is 
one of the major T cell functional impairments that occur in chronic HIV-infection. 
CD4+ T cells often play an important role in the generation of optimal CD8+ T cell 
responses in an ongoing infection. CD4+ helper T cells produce IL-2, which is a T cell 
growth factor that supports HIV-specific CD8+ T cell survival and memory T cell 
formation. Since CD4+ T cells are the main target of HIV, there is a dramatic 
reduction in CD4+ T cell counts in untreated HIV-infection. This renders the HIV-
specific CD8+ T cell “helpless”, and contributes to HIV-specific CD8+ T cell 
exhaustion in progressive HIV infection (210). Zimmerli et al. showed that HIV-1-
specific IFN-γ/IL-2-producing CD8+ T cells are capable of driving their own 
proliferation in the absence of CD4+ T cell help (211). To this end, we followed up to 
see whether HIV-1-specific IFN-γ/IL-2-producing CD8+ T cells activated by 
heteroclitic peptide stimulation can also drive their clonal expansion. PBMC from 
HIV-infected subjects that showed higher cytokine responses to heteroclitic peptides 
in ELISPOT assays were further cultured for 7 days with the heteroclitic peptide that 
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induced the highest cytokine responses. We found that heteroclitic peptides enhanced 
HIV-specific CD8+ T cell proliferation relative to reference peptides in almost half of 
the cases where reference / heteroclitic HIV-peptide pairs were compared. Since IL-2 
is a T cell growth factor that plays an important role in driving T cell clonal expansion 
and differentiation, we expected heteroclitic peptides that enhanced IL-2 production to 
also enhance HIV-specific CD8+ T cell proliferation. Surprisingly, HIV-specific CD8+ 
T cell proliferation was not enhanced in at least one case where IL-2 production was 
increased. Our data suggest that enhanced CD8+ T cell proliferation by heteroclitic 
peptides in many cases is independent of detectable IL-2 production. All the 
heteroclitic peptides tested in proliferation assays enhanced IFN-γ production. Ahmed 
et al. showed that loss of IL-2 production and proliferation capacity are the early signs 
of functional impairment observed in LCMV-specific CD8+ T cells. IFN-γ production, 
which is persistent, eventually becomes defective in severe T cell exhaustion (184). 
This T cell functional impairment has been documented in chronic HIV-infection as 
well (159,160). Several studies have shown that a significant fraction of HIV-specific 
CD8+ T cells lose the ability to produce IFN-γ in chronic HIV-infection, a 
phenomenon which indicates severe T cell exhaustion (212-214). Our finding that 
heteroclitic HIV-peptides enhanced proliferation and cytokine production relative to 
the native HIV-peptide epitope suggests that heteroclitic peptide stimulation either 
selectively stimulates non-exhausted T cells or restores “exhausted” HIV-specific 
CD8+ T cells to a functional or even polyfunctional state. Retention of polyfunctional 
HIV-specific CD8+ T cells, which are capable of producing cytokines and 
proliferating, is an attribute found in only a minority of HIV-infected, ART-naïve 
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viremic controllers called long-term nonprogressors (LTNP) (215). Hence, our results 
suggest that heteroclitic peptide stimulation could possibly stimulate activation of the 
same polyfunctional T cells that help LTNP keep viremia in check. 
In progressive HIV infection, chronic expression of PD-1 molecules on HIV-
specific CD8+ T cells correlates with failure to contain viremia (177). In addition, 
HIV-specific CD8+ T cells in LTNP express a significantly lower amount of PD-1, 
which is associated with their ability to contain HIV viremia (215). Several 
interventions aimed at improving exhausted T cell responses employed monoclonal 
blocking antibodies against PD-1 or its ligands or introduced exogenous costimulatory 
molecules such as 4-1BB during T cell activation. All of these interventions to a 
significant extent restored or improved the effector functions of responding T cells 
(68,216). However, native HIV-peptide epitopes were utilized in stimulating these 
HIV-specific CD8+ T cells in all the interventions. For the first time, we demonstrated 
that heteroclitic variants of these native HIV-peptide epitopes could improve the 
character of HIV-specific CD8+ T cell responses relative to their reference epitopes, 
without either introducing exogenous costimulatory molecules or blocking inhibitory 
receptors. Expression of PD-1 on proliferating HIV-specific CD8+ T cells stimulated 
with heteroclitic peptides was significantly low relative to HIV-specific CD8+ T cells 
stimulated with reference peptides in almost half of the peptide pairs compared. This 
finding suggests unique features of heteroclitic peptides in reducing T cell 
“exhaustion” while still enhancing proliferation and cytokine production in 
responding CD8+ T cells. Comparison of cases where PD-1 expression was lower with 
cases where HIV-specific CD8+ T cell proliferation was enhanced showed no 
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significant correlation between lower PD-1 expression and enhanced proliferation. 
This could either mean that heteroclitic peptides select for distinct heterogeneous 
subsets of HIV-specific CD8+ T cells, which partly explains the difference in 
frequency of PD-1 low cells induced by heteroclitic peptides or that activation signals 
generated by heteroclitic peptide stimulation somehow bypass the PD-1 signaling 
pathway, thereby allowing enhanced proliferation even of PD-1hi CD8+ T cells. 
However, since elevated PD-1 expression in HIV and other chronic infections is 
associated with T cell exhaustion and disease progression, lower expression of PD-1 
generated by heteroclitic peptides may enhance CD8+ T cell effector function and 
limit disease progression. Normally, inhibitory signals delivered by PD-1 
downregulate TCR signaling through direct dephosphorylation of intracellular 
signaling intermediates. The phosphatases (SHP-1 and SHP-2) associated with PD-1 
dephosphorylate CD3ζ and prevent the phosphorylation of ZAP-70 and PKCθ (85). A 
possible explanation for the negligible effects of PD-1 signaling on HIV-specific 
CFSEdim CD8+ T cells responding to heteroclitic peptide stimulation as we have 
observed could be attributed to increased tyrosine phosphorylation of ZAP-70 and 
TCR ζ chains in CTL stimulated with heteroclitic peptides relative to native peptide-
stimulated CTL, as was reported by Salazar et al. (202). Again, this supports our 
suggestion that heteroclitic peptides can potentially bypass exhaustion induced by 
reference peptides. There was no correlation between the type of cytokine induced by 
heteroclitic peptides and lowered PD-1 expression (data not shown). Even though IL-2 
is a T cell growth factor, studies indicate it can increase the expression of PD-1. A 
study by Fauci et al. showed that culture of purified T cells with common γ-chain 
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cytokines such as IL-2, IL-7, IL-15, and IL-21 markedly enhanced PD-1 expression in 
vitro (217). This observation was confirmed in vivo when they demonstrated that 
PBMC isolated from HIV-infected subjects expressed higher levels of PD-1 following 
IL-2 immunotherapy (217). This supports our finding that heteroclitic-HIV peptides 
induced lower PD-1 expression on HIV-specific CD8+ T cells in the absence of 
detectable IL-2. The goal of heteroclitic HIV-variant peptide stimulation is to generate 
HIV-specific CD8+ T cells with enhanced effector responses towards the native 
antigen. Studies in our laboratory showed by additive ELISPOT assays that reference 
peptides A2-7, A2-8, A2-9 and their respective heteroclitic analogs stimulated the 
same subset of HIV-specific CD8+ T cells (206). Since the amino acid substitutions 
we made in the variant peptide sequences were not at the positions harboring HLA 
anchor residues, we do not expect any alteration in their HLA-binding affinity relative 
to the reference peptides. This T cell cross-reactivity, however, suggests that the 
enhanced responses observed in CD8+ T cells stimulated with heteroclitic peptides 
could be attributed to differential intracellular signaling of the responding CD8+ T 
cells rather than recognition of reference and variant peptides by different T cells. 
Even though additive ELISPOT assays suggest that heteroclitic peptides 
stimulated the same CD8+ T cell subsets as the reference peptides, we still cannot rule 
out the possibility that heteroclitic peptides may also stimulate CD8+ T cells that are 
not specific for the native peptide epitope. The substitution of threonine at position 2 
of a well-characterized HLA-A2-restricted melanoma antigen (gp100209-217) with 
methionine (gp1002M) significantly enhanced pMHC binding affinity and antigen 
presentation (218,219). However, only 25% of T cells from PBMC of melanoma 
80 
 
patients stimulated with melanoma peptide analog gp1002M were able to recognize the 
native peptide epitope (220). It was also confirmed in an independent study that 
gp1002M-specific T cell cross-reactivity with the wild-type melanoma antigen is 2-3 
orders of magnitude lesser than to the gp1002M peptide (221). Since the aim of 
heteroclitic peptide stimulation is to enhance responses in HIV-specific CD8+ T cells 
with high avidity for native-HIV proteins, inducing T cells that do not recognize 
native HIV epitopes or T cells that mask the desired responses would not be 
beneficial. Tetramer-stained HIV-specific CD8+ T cells expanded with reference 
peptides in proliferation assays can be stimulated with heteroclitic peptides to monitor 
the frequency of cross-reactive HIV-specific CD8+ T cells responding to heteroclitic 
peptide stimulation. Also, additive proliferation assays in which PBMC from our 
HIV-infected subjects would be cultured in separate tubes for 7 days with the 
reference peptides or heteroclitic peptides as explained in the methods section, and a 
combination of the reference peptide with the heteroclitic peptides in the same tube 
could be performed in order to investigate heteroclitic peptide-driven T cell cross-
reactivity with the native-HIV peptide. An additive response would be expected if 
different subsets of HIV-specific CD8+ T cells were responding to the peptide 
stimulation. However, if both peptides stimulated the same CD8+ T cell subset, the 
percentage of CFSEdim CD8+ T cells in the PBMC population that was stimulated with 
both reference and heteroclitic peptides would be equal to the percentage of CFSEdim 
CD8+ T cells in the PBMC population that was stimulated with the heteroclitic 
peptide. We couldn’t measure the baseline expression level of PD-1 on CD8+ T cells 
for post-stimulation comparison due to a shortage of PBMC. However, we speculate 
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that heteroclitic peptides stimulated the same subset of HIV-specific CD8+ T cells 
based on previous ELISPOT results (206). 
Finally, we examined the effect of 4-1BBL costimulation or blockade of the 
PD-1 pathway on CD8+ T cells responding to heteroclitic peptide stimulation. The 
balance of costimulatory and inhibitory signals delivered via the TCR and other cell 
surface signaling molecules to T cells ultimately determines their effector responses. 
Several studies have shown that altering both the positive and negative signals 
delivered to antigen-specific T cells in some cancer and infectious disease models can 
potentially be therapeutic (183,206,222,223). Also, since flow cytometry was not done 
before day 7 due to shortage of cells, some dividing cells might be undergoing cell 
death through activation and it is possible that PD-1 blockade would prevent apoptotic 
cell death usually induced by PD-1 signaling. One way by which heteroclitic peptides 
induce better T cell responses is by increasing tyrosine phosphorylation of ZAP-70 
and TCR ζ chains (202), which is normally inhibited by PD-1 signaling, elimination of 
the PD-1 signal should further improve the effect of heteroclitic peptide stimulation on 
the responding HIV-specific CD8+ T cells. Therefore, we blocked the PD-1/PD-L1/2 
pathway during peptide stimulation of HIV-specific CD8+ T cells. Indeed, blocking 
the PD-1 signaling pathway further enhanced proliferation of HIV-specific CD8+ T 
cells stimulated with heteroclitic peptides. Since 4-1BB costimulates T cells 
independently of the major T cell costimulatory molecule CD28 and humans 
accumulate CD28– T cells with age, we decided to also stimulate the HIV-specific 
CD8+ T cells with peptides in the presence of 4-1BBL. Addition of exogenous 4-
1BBL fusion protein as a source of T-cell costimulation also enhanced proliferation 
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and reduced PD-1 expression on HIV-specific CD8+ T cells responding to heteroclitic 
peptides. A combination of both 4-1BBL costimulation and PD-1 blockade showed an 
additive effect on HIV-specific CD8+ T cells stimulated with the reference peptides 
but was not tested with heteroclitic peptides. 
This study characterized the effects of heteroclitic HIV-peptide stimulation on 
HIV-specific CD8+ T cell effector responses such as cytokine production and clonal 
expansion, which are impaired with T cell exhaustion. We identified an additional 29 
instances of heteroclitic peptide activity, and showed that IFN-γ and IL-2 production 
were enhanced in HIV-specific CD8+ T cells responding to these peptides. We 
demonstrated that heteroclitic variants of native HIV-peptides are capable of 
enhancing HIV-specific CD8+ T cell proliferation relative to native epitopes, and that 
improved IL-2 responses are not always associated with enhanced proliferation. The 
heteroclitic variant peptides employed in this study produced promising results, which 
could potentially guide the design of other heteroclitic HIV-peptide variants. In this 
study, we only generated twenty-four variant peptides from A2-7, A2-8, A2-9, and 
A2-Gag reference peptides (i.e. six variants per peptide set). This was carried out by a 
single conservative or semiconservative aa substitution at residues distinct from the 
main MHC anchors. These substitutions often induced better HIV-specific CD8+ T 
cell responses than the reference peptide, consistent with the findings of Sette et al. 
(203). Also, we did not find a significant correlation between enhanced proliferation 
and lower PD-1 expression with heteroclitic peptide stimulation in this study. Finally, 
we showed that manipulating T cell costimulatory and/or inhibitory signals could 
further benefit the T cells responding to heteroclitic peptide stimulation in terms of 
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proliferation. This study further advances our knowledge on the ability of heteroclitic 
peptides to enhance effector functions of HIV-specific CD8+ T cells. 
Analysis of aa substitutions in the reference peptide sequences, that made the 
variant peptides more antigenic (heteroclitic) could be used to inform the design of 
more potentially heteroclitic variants with substitutions at multiple positions. It is 
important to note that heteroclitic peptides employed in this study were variants of 
immunodominant epitopes. Inter-individual variability in heteroclitic responses could 
be attributed to the polymorphic nature of HLA presenting the immunodominant HIV 
epitopes and studies show that HIV immunodominant epitopes, in the context of their 
HLA-restriction do not often reflect an individual's overall HIV-specific CD8+ T cell 
response (224). This may limit generalizability in terms of vaccine development. 
However, if heteroclitic peptides enhance antiviral immunity, personalized therapeutic 
HIV vaccine would not demand inordinate effort or expense relative to genotyping 
and phenotyping, which is already standard of care for HIV infection. Our findings 
justify further investigation of the incorporation of heteroclitic peptides into HIV 
vaccines. 
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5.0 Conclusions and Future Directions 
 This study has generated additional knowledge on the potential benefits of 
incorporating heteroclitic-HIV peptides into HIV therapeutic vaccines to induce 
stronger and better HIV-specific CD8+ T cell responses. We have shown that 
heteroclitic peptides can alter both the magnitude and character of HIV-specific CD8+ 
T cell responses. Since chronic stimulation with wild-type HIV epitopes is associated 
with HIV-specific CD8+ T cell exhaustion, a longer time-frame would be required to 
determine whether or not chronic stimulation with heteroclitic HIV-peptides would 
also lead to T cell functional impairment. Heteroclitic peptide stimulation in this study 
only lasted 24 hours (ELISPOT) or 7 days (proliferation assay). Since PD-1 
expression did not hinder HIV-specific CD8+ T cell responses when stimulated with 
heteroclitic peptides compared to reference peptides, it is worth investigating whether 
activation signals generated by heteroclitic peptide stimulation bypass or overwhelm 
the PD-1 signaling pathway in some way. This could be investigated by carrying out a 
microarray analysis to examine what genes are turned on or repressed in PD-1 
expressing CD8+ T cells stimulated with heteroclitic peptides compared to those 
stimulated with reference peptides. This could provide insight into how the 
TCR/heteroclitic peptide interactions modulate T cell responses. Other T cell 
inhibitory molecules that have been implicated in T cell exhaustion include TIM-3, 
LAG-3, CD160, CTLA4, 2B4 and SLAM. We only investigated the effect of 
heteroclitic peptides on PD-1 expression in this study. Further investigation should 
determine whether or not heteroclitic peptides modulate the expression of other co-
inhibitory molecules and if this contributes to the enhanced T cell responses generated 
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by heteroclitic peptides. Altogether, this information could be useful for designing 
heteroclitic peptides that improve effector responses of HIV-specific CD8+ T cells 
with high avidity for native-HIV epitopes. 
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Appendix A:  General characteristics of study subjects with heteroclitic responses. 
 
aID bVirus 
load 
cCD4+ T 
cells/μl 
dCD4+ T 
cell  nadir 
CD8+ T 
cells /μl 
eDuration of 
infection  
fHAART 
       
007 3.87 8 8 1239 >17 years No 
028 ≤1.30 140 0 1180 >17 years Yes 
214 ≤1.30 189 90 576 >6 years Yes 
078 4.44 228 32 1007 >17 years Yes 
125 ≤1.60 248 59 464 >14 years Yes 
011 1.78 280 63 2450 >17 years Yes 
283 4.25 352 352 752 >1 year No 
166 ≤1.30 364 200 663 >11 years Yes 
212 ≤1.70 378 300 423 >6 years Yes 
244 ≤1.30 475 51 817 >3 years Yes 
282 ≤1.30 476 476 532 >1 year Yes 
039 ≤1.30 483 24 1426 >17 years Yes 
148 ≤1.30 533 6 468 >13 years Yes 
126 ≤1.30 620 164 600 >14 years Yes 
001 ≤1.30 638 51 792 >18 years Yes 
043 ≤1.30 675 324 420 >17 years Yes 
230 ≤1.30 696 390 1296 >4 years Yes 
277 ≤1.30 696 621 986 >1 year Yes 
071 ≤1.30 768 418 1320 >17 years Yes 
115 ≤1.30 768 204 1248 >15 years Yes 
134 ≤1.30 810 96 504 >14 years Yes 
045 ≤1.30 868 209 1260 >17 years Yes 
237 ≤1.30 952 480 1836 >4 years Yes 
035 1.48 1020 176 3300 >17 years Yes 
233 1.31 1088 1568 1050 >4 years Yes 
 
aSubjects were sequentially coded as they enrolled in the study and are tabulated in 
order of increasing CD4+ T cell counts. 
 
bVirus loads obtained for the time of testing from clinical charts are expressed as log10 
copies HIV RNA/mL plasma. 
 
cNumber of CD4+ and CD8+ T cells/L peripheral blood at the time of testing for each 
subject. 
 
dCD4+ T cell nadir is the lowest recorded CD4+ T cell count from each subjects’ 
clinical chart. 
 
eDuration of infection is based on the earliest record of known HIV-seropositive 
status. 
 
fWhether or not subjects were receiving highly active antiretroviral therapy at time of 
testing is noted. 
